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Summary 
 
Up to 50% of patients with the clinical syndrome of heart failure have preserved 
left  ventricular  systolic  function  (HF-PSF).    Invasive  studies  utilising  cardiac 
catheterisation have demonstrated that patients with HF-PSF have abnormalities of left 
ventricular (LV) relaxation and filling, or LV diastolic dysfunction.  As a result, it has 
been proposed that LV diastolic dysfunction is the primary pathophysiological process 
in  HF-PSF.    However,  population-based  studies  have  shown  that  there  is  poor 
correlation between the presence of LV diastolic dysfunction and the presence of heart 
failure.  This controversy has led to a search for alternative pathophysiological processes 
which could potentially cause HF-PSF.  There are some data to suggest that patients 
with HF-PSF have a combination of LV diastolic dysfunction, or ‘LV stiffness’, and 
large artery stiffness, when compared with normal subjects and patients with systemic 
hypertension.    This  implies  that  the  interaction  between  the  left  ventricle  and  the 
vasculature  is  dysfunctional  and  a  potential  cause  of  HF-PSF.    Although  there  are 
limited data on arterial stiffness in HF-PSF, there have been no studies examining other 
parameters  of  vascular  function  in  HF-PSF  and  vascular  function  has  never  been 
formally compared in cohorts of patients with HF-PSF and heart failure due to reduced 
LV systolic function (HF-RSF).   16 
The studies presented in this thesis were designed to further characterise vascular 
function in HF-PSF and to compare vascular function between patients with HF-PSF, 
patients with HF-RSF and control subjects.  I used non-invasive techniques to assess 
parameters of arterial function, such as arterial stiffness and arterial endothelial function.  
I also evaluated parameters of venous function, namely venous capacitance and venous 
endothelial function. 
Arterial  stiffness,  measured  by  aortic  pulse  wave  velocity  (PWV),  was 
significantly  elevated  in  HF-PSF  compared  to  both  HF-RSF  and  control  groups, 
implying that HF-PSF is indeed associated with greater arterial stiffness.  In contrast, 
arterial diastolic waveform analysis failed to show any significant differences in derived 
parameters of arterial compliance between the three study groups, which may be due to 
the  fact  that  all  three  groups  were  matched  for  underlying  coronary  heart  disease, 
reducing the ability of the technique to differentiate between groups. 
Using Laser Doppler iontophoresis, I demonstrated that HF-PSF and HF-RSF 
subjects  have  impaired  microvascular  responses  to  both  acetylcholine  and  sodium 
nitroprusside.    This  suggests  that,  rather  than  being  solely  a  primary  disorder  of 
endothelial function, impaired control of vascular tone in HF-PSF reflects significant 
vascular smooth muscle dysfunction.  It is not certain if arterial smooth muscle and/or 
endothelial dysfunction is secondary to the inflammatory and neurohumoral activation 
associated with the heart failure syndrome, or a primary pathophysiological factor in the 
development of either form of heart failure.   17 
As  regards  venous  function,  patients  with  HF-PSF  had  a  lower  venous 
capacitance than patients with HF-RSF (but similar venous capacitance to the controls).  
Increased venous capacitance may represent a compensatory response in heart failure 
that is less marked or absent in HF-PSF, compared to HF-RSF.  Venous endothelial 
function  was  measured  with  the  Aellig  dorsal  hand  vein  technique.    It  was  not 
technically possible to complete an Aellig study in the whole patient cohort, resulting in 
fewer data being available for analysis.  Despite this, both heart failure groups appeared 
to  have  impaired  venodilatation  in  response  to  acetylcholine,  compared  to  controls, 
although this apparent difference was not statistically significant.  
While  the  studies  of  venous  capacitance  and  endothelial  function  were  not 
conclusive, they suggest that venous function may be abnormal in HF-PSF.  The finding 
that endothelial and smooth muscle control of arterial tone was impaired in both HF-PSF 
and HF-RSF may indicate a similar primary pathophysiological process, or indeed a 
similar  response  to  inflammatory  and  neurohumoral  activation  in  heart  failure.  I 
conclude that the data presented in this thesis supports the hypothesis that HF-PSF is 
associated with increased arterial stiffness, which in combination with increased LV 
stiffness is likely to result in impaired ventriculo-vascular coupling.  This process is 
likely to be an important pathophysiological factor in the development of HF-PSF. 
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1.1  The Heart Failure Syndrome 
 
1.1.1  A definition of heart failure 
There  are  several  contemporary  definitions  of  heart  failure,  most  of  which  are 
unsatisfactory, as they do not encompass all aspects of the condition. 
One of the most widely quoted definitions of heart failure was first proposed by Paul 
Wood  in  1950,  and  adapted  slightly  by  Braunwald  et  al  in  1982.    In  Braunwald’s 
definition, heart failure is described as “…a pathophysiological state in which the heart 
is  unable  to  pump  blood  at  a  rate  commensurate  with  the  requirements  of  the 
metabolising tissues or can do so only from an elevated filling pressure.”[1] 
Many modern texts define heart failure as a clinical syndrome characterised by typical 
symptoms, clinical signs and chest radiograph appearance, which may result from a 
number of different disease processes, rather than being a disease in its own right.  Both 
European and American guidelines on the diagnosis and management of chronic heart 
failure advise evaluation of patient symptoms and clinical signs in  conjunction with 
investigation results to make a diagnosis of heart failure.[2, 3]  This is highlighted by the 
frequent use of clinical scoring systems, such as the Boston criteria,[4] to determine the 
likelihood of the presence of heart failure.   
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1.1.2  Epidemiology of heart failure 
The importance of heart failure as a major public health problem has been described in 
multiple review articles, such as those written by McMurray et al [5] and Mehta et al.[6] 
The following section provides a summary of the most important published data on the 
epidemiology of heart failure. 
 
1.1.3  Prevalence of heart failure 
Heart failure is common, particularly in older individuals. The largest body of evidence 
available on the prevalence of heart failure is from large cohort studies carried out in the 
United States. In the Framingham heart study, prevalence of heart failure in 50-59 year-
olds was 0.8% rising to 9.1% in those above 80 years of age.[7] Another extremely large 
cohort  study,  The  United States  National  Health  And  Nutrition Examination  Survey 
(NHANES), reported the prevalence of heart failure to be 8% in subjects over 65 years 
of age.[8] 
 
1.1.4  Incidence of heart failure 
Less information is available regarding the incidence of heart failure, with most data 
once again resulting from large population-based studies in the United States. In the 
Framingham heart study, the annual incidence of heart failure was 0.3% in men and 
0.2% in women aged 50-59 years, rising to 2.7% in men and 2.2% in women aged 80-89 
years.[7]  Another  population-based  study  conducted  in  the  United  States  was  the   21 
Rochester epidemiology project.[9] In this study, investigators examined the incidence 
of heart failure during 1981 in Olmsted County, Minnesota.  During the study period, 46 
new diagnoses of heart failure were made in patients aged 0-74 years. Overall, this 
equates to an annual heart failure incidence of 110 cases per 100,000 population.  As 
noted in the Framingham study, the incidence of heart failure in the Olmsted study was 
higher in males than in females (157 versus 71 per 100,000 population). 
 
1.1.5  Prognosis of heart failure 
Heart failure is lethal, with a particularly high early mortality, and carries a prognosis 
similar to many common forms of cancer.  
The Framingham study showed that men with a diagnosis of heart failure have one-year, 
five-year  and  ten-year  mortality  rates  of  43%,  75%  and  89%,  respectively.  The 
corresponding mortality rates in women at one, five and ten years were slightly better at 
46%,  62%  and  79%,  respectively.[10] The  NHANES  study  also  provided  long-term 
follow-up mortality data in patients with heart failure. In this study population, ten-year 
mortality rate in those aged 25-74 years was 49.8% in men and 36% in women.[8] These 
mortality rates compare favourably with those reported from the Framingham study. 
This discrepancy has been attributed to the fact that symptoms of heart failure in this 
study  were  self-reported,  rather  than  based  purely  on  a  score  derived  from  clinical 
criteria, such as was employed in the Framingham study.[10] In addition, the patients 
were not hospitalised, implying that their symptoms were less severe.[5, 6]   22 
The Rochester epidemiology project also found the survival after a diagnosis of heart 
failure to be poor. In the cohort presenting in 1981 mortality was 20% at six months and 
34% at one year.[9] The same group has reported longer-term survival data on another 
cohort of patients who presented with heart failure ten years later, in 1991. The overall 
mortality in the 1991 cohort was 24% at one year and 65% at five years. [11] 
In  summary,  several  large  epidemiological  studies  have  repeatedly  shown  that  heart 
failure  is  common  and  carries  a  poor  prognosis,  underlining  the  importance  of  the 
condition as an area where further research and development of new therapies are vital. 
 
1.2  Pathophysiology of Heart Failure 
 
1.2.1  Elevated intra-cardiac pressure 
Central to the pathophysiology of heart failure is the development of elevated intra-
cardiac pressure. The commonest precipitant is myocardial damage and the development 
of  impaired  LV  systolic  contraction  following  myocardial  infarction  or  ischaemia.  
Impaired LV systolic contraction leads to a chain of compensatory mechanisms in order 
to  maintain  stroke  volume  and  cardiac  output.    The  most  important  compensatory 
mechanism  is  dilation  of  the  left  ventricle,  increasing  left  ventricular  end-diastolic 
pressure (LVEDP), or pre-load.  According to Frank-Starling’s law, increasing LV pre-
load stretches myocardial fibres (increasing sarcomere length) and will increase force of 
contraction, stroke volume and cardiac output.[12]    23 
However, with progressive deterioration of LV systolic contraction, the left ventricle 
will continue to dilate and the LVEDP and subsequent myocardial stretch ultimately 
exceed the level that will result in improved stroke volume (figure 1.1).  During the 
diastolic phase of the cardiac cycle, high LV pressure results in elevation of the left 
atrial pressure.  As left atrial pressure rises, pulmonary capillary hypertension develops, 
resulting in transudation of fluid from intra-vascular to extra-vascular compartments, 
causing  pulmonary  oedema.  Over  time,  pulmonary  vascular  remodelling  occurs  and 
pulmonary vascular resistance rises.  This increases right ventricular afterload and end-
diastolic pressure, starting a cascade of compensatory mechanisms on the right side of 
the heart. When the right ventricle decompensates, the right atrial and systemic venous 
pressure rise and the characteristic features of peripheral oedema, hepatic congestion and 
ascites develop. 
   24 
Figure 1.1:   
Frank-Starling  curve  demonstrating  that  increased  left  ventricular  end-diastolic  pressure  results  in 
increased stroke volume up to a point when the curve plateaus and beyond which the left ventricle will 
decompensate and stroke volume may fall. The curve representing the normal resting heart is represented 
by the solid, black line. With increased venous return (preload) or increased left ventricular inotropy, the 
curve moves up and to the left (dashed red line). With increased left ventricular afterload, or decreased 
inotropy, the curve moves down and to the right (dashed blue line). 
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1.2.2  Neurohumoral activation 
Heart failure is associated with marked vasoconstriction and retention of salt and water.  
Initially  an  adaptive  response  in  an  effort  to  improve  arterial  pressure  and  tissue 
perfusion, ultimately these processes become maladaptive. Vasoconstriction and volume 
overload in heart failure are secondary to neurohumoral activity.  Specifically, increased 
plasma concentrations of angiotensin II, norepinephrine and endothelins all contribute to 
the increased vascular tone observed in heart failure.  The resulting vasoconstriction 
exacerbates poor tissue perfusion and stimulates further neurohumoral activity.  Volume 
overload results from the actions of aldosterone.  Reduced cardiac output results in renal 
arterial under-filling.  This stimulates the renin-angiotensin-aldosterone system (RAAS) 
to constrict peripheral vessels via action of angiotensin II to improve central arterial 
perfusion pressure, and to retain sodium and water via action of aldosterone.  Arterial 
under-filling  also  stimulates  baroreceptors,  leading  to  activation  of  the  sympathetic 
nervous system, increased norepinephrine activity and further activation of the RAAS.  
This over-activation of the RAAS ultimately becomes maladaptive, and fluid overload 
results.[13]  In addition to angiotensin II and norepinephrine, endothelins circulate in 
high concentrations and exacerbate vasoconstriction in heart failure.[14] 
As  a  compensatory  mechanism,  endogenous  vasodilators  are  released  from  cardiac 
tissue, predominantly in response to circulating volume overload and myocardial stretch.  
These endogenous vasodilators are known as the natriuretic peptides and in addition to 
vasodilatation,  stimulate  salt  and  water  excretion  from  the  kidney.[15]    One  of  the   26 
natriuretic peptides, brain-type natriuretic peptide (BNP), is predictably found in higher 
plasma concentrations in patients with the clinical syndrome of heart failure.  More 
recently, evidence has shown BNP concentration to be associated with disease severity 
and a powerful predictor of clinical outcome in both HF-RSF [16] and HF-PSF.[17]  
Heart failure is also an inflammatory process, associated with profound activation of 
cytokine pathways leading to production of reactive oxygen species.  This inflammatory 
over-activity and free radical production has been implicated in the pathophysiology of 
vascular dysfunction in HF-RSF.[18] 
There  is  profound  neurohumoral  activity  in  heart  failure  involving  several  different 
pathways.    Excess  neurohumoral  activity  in  heart  failure  has  been  implicated  as  a 
potential cause or exacerbating factor in the peripheral vasoconstriction and vascular 
dysfunction seen in the heart failure syndrome. 
 
1.3  Heart Failure with Preserved Left Ventricular Systolic Function 
 
1.3.1  Definition of HF-PSF 
Heart failure with preserved systolic function can be defined as: the syndrome of heart 
failure in the presence of normal LV systolic function and the absence of significant 
valvular heart disease, cardiac dysrhythmia, right ventricular dysfunction or high output 
states  such  as  anaemia.    This  definition  is  straightforward  but  relies  heavily  on  the 
statement that LV systolic function is ‘normal’.  The definition of normal LV systolic   27 
function is not straightforward and has been the subject of debate.  Most centres use LV 
ejection  fraction  (LVEF)  to  quantify  LV  systolic  function.    Due  to  the  widespread 
availability  of  non-invasive  imaging  techniques,  such  as  echocardiography  and 
radionuclide  imaging,  LVEF  can  be  obtained  easily.    As  LVEF  is  expressed  as  a 
percentage of LV diastolic volume, it gives one a figure that is easy to understand and 
lends itself to comparison between groups with statistical analysis.  These factors have 
greatly contributed to the widespread use of LVEF as a means of describing LV systolic 
performance.  In the literature, the LVEF considered to represent ‘normal’ LV systolic 
function varies widely between 40 and 70%,[19-21] but most groups define preserved 
LV systolic function as a LVEF >50%.  The LVEF value deemed to represent ‘normal’ 
LV systolic function obviously impacts on incidence and prevalence figures as detailed 
below in sections 1.3.3 and 1.3.4. 
 
1.3.2  Epidemiology of HF-PSF 
Much has been learned about the epidemiology of HF-PSF in the last ten years. It is now 
apparent from multiple epidemiological studies that patients with HF-PSF constitute a 
significant proportion of the total burden of heart failure. Comprehensive review articles 
on the epidemiology of HF-PSF have been published by Vasan et al [22] and more 
recently  by  Hogg  et  al.[23]  The  following  section  comprises  an  overview  of  the 
epidemiology of HF-PSF. 
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1.3.3  Prevalence of HF-PSF 
Although  the  populations  studied  are  heterogeneous,  with  variable  definitions  of 
preserved  systolic  function,  the  evidence  from  multiple  cross-sectional,  population-
based studies tends to agree with incidence studies, and suggests that HF-PSF makes up 
a significant proportion of the overall burden of heart failure worldwide.  Prevalence of 
HF-PSF  (LVEF  ≥50%)  in  the  Framingham  study  was  51%.[24]  These  results  are 
mirrored in the Cardiovascular Health Study, in which the prevalence of PSF (LVEF 
≥50%) among patients with heart failure was 55%.[20] Another population-based study, 
looking at registry data of heart failure admissions to ten hospitals, was the Management 
to Improve Survival in Congestive Heart Failure (MISCHF) Study.  In the MISCHF 
study, 42% of patients had a LVEF ≥ 40% and 24% of patients had a LVEF ≥ 50%.[25]  
The Helsinki Aging Study looked at older subjects (75-86 years) with heart failure.  The 
threshold LVEF for ‘preserved’ systolic function was high at >70%.  In spite of this 
stringent definition of preserved LV systolic function, a significant proportion of this 
cohort  of  patients  (51%)  had  HF-PSF.[21]  Follow-up  data  from  the  Rochester 
Epidemiology Project heart failure population indicate that the prevalence of HF-PSF is 
high, and has risen in the last 15 years.  The prevalence of preserved systolic function 
(LVEF >50%) among patients with heart failure increased from 38% to 54% between 
1987 and 2001,[26] although the authors note that this phenomenon is probably partly 
due to increased clinician awareness of HF-PSF in recent years, leading to more frequent 
recognition and diagnosis of HF-PSF.    29 
 
1.3.4  Incidence of HF-PSF 
As with epidemiological data on HF-RSF, there is less published information available 
about the incidence of HF-PSF than prevalence. The Rochester group found that of all 
patients admitted with a new diagnosis of heart failure over a one-year period (1991), 
43% had preserved LV systolic function, defined as an ejection fraction of ≥50%.[11] 
Similarly, the Cardiovascular Health Study population had a high incidence of HF-PSF. 
Over the study period there were 597 incident cases of heart failure, diagnosed in the 
community, rather than in hospital, of which 60% had a LVEF of ≥55% at time of 
diagnosis.[20, 27]  More recently, Bhatia et al have reported a study of 2802 patients 
admitted to 103 Canadian hospitals with a new diagnosis of heart failure. In this study 
population, the incidence of HF-PSF (LVEF ≥50%) was 31%.[28] 
 
1.3.5  Prognosis of HF-PSF 
Previously reported morbidity and mortality data from the Cardiovascular Health Study 
[29] and the CHARM study [19] suggest that HF-PSF is a more benign condition that 
HF-RSF.  However, recently published data from Canada would indicate that outcome is 
similar  in  both  HF-PSF  (LVEF  >50%)  and  HF-RSF  (LVEF  <40%)  with  one  year 
mortality rates of 22% and 26%, respectively (p=0.08).[28] 
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1.4  Pathophysiology of HF-PSF 
 
The pathophysiology of HF-PSF has not yet been fully established.  A commonly held 
view is that HF-PSF is due to diastolic dysfunction of the left ventricle.  More recently, 
it has been proposed that abnormalities of interaction between the left ventricle and the 
vasculature may lead to HF-PSF.  In this section I will provide an overview of what is 
currently known about LV diastolic dysfunction and ventriculo-vascular interaction, and 
the relevance of both in the context of HF-PSF pathophysiology. 
 
1.4.1  Diastolic dysfunction of the left ventricle 
The term ‘diastolic dysfunction’ refers to abnormalities of relaxation and filling of the 
left ventricle, rather than contraction and emptying.  It is a commonly held view that 
diastolic dysfunction of the left ventricle is the primary pathophysiological process in 
HF-PSF.[30, 31]  Left ventricular diastolic function is a complex process that has been 
extensively  studied.    A  comprehensive  account  of  current  information regarding  the 
physiology of normal LV diastolic function and the pathophysiology of LV diastolic 
dysfunction is beyond the scope of this introduction.  Kass et al have recently reviewed 
this subject.[32] 
For the purposes of this introduction I will focus on a summarised description of LV 
diastolic function and dysfunction, and how LV diastolic dysfunction may be implicated 
in the pathophysiology of HF-PSF.   31 
 
1.4.2  Active relaxation of the left ventricle 
Left ventricular diastole consists of two phases: active relaxation and passive filling.  
Relaxation of the left ventricle is an active process, beginning at the end of ventricular 
systolic  contraction.    LV  relaxation  is  a  complex  process,  which  relies  on  multiple 
events at molecular level, including myocyte calcium handling, active phosphorylation 
and  actin-myosin  cross-bridge  detachment  to  name  but  a  few.    All  of  these  events 
consume energy, and can therefore be attenuated during myocardial ischaemia, resulting 
in abnormal LV relaxation.  This ischaemic failure of relaxation can be due to coronary 
heart disease, where normal myocardial oxygen requirements are not adequately met due 
to  poor  arterial  supply.    Left  ventricular  hypertrophy  (LVH)  also  causes  ischaemic 
failure of LV relaxation.  The increased myocardial mass in LVH has abnormally high 
oxygen requirements and demand can outstrip supply even in the absence of coronary 
heart disease.  Co-existing LVH and coronary heart disease can result in a powerful 
substrate  for  impaired  LV  relaxation.[33,  34]  Left  ventricular  relaxation  is  also 
dependent  on  venous  return  and  LV  pre-load, which  I  discuss  in  section  1.5.7,  and 
duration of systole and LV afterload, which I discuss in section 1.4.5.  
Delayed onset or slow active relaxation results in attenuation of the normal fall in LV 
pressure during diastole, and a net rise in LV diastolic pressure. 
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1.4.3  Passive filling of the left ventricle 
Passive filling of the left ventricle is the other important phase of effective diastolic 
function.  It is dependent on the intrinsic characteristics of the LV wall, usually termed 
‘LV diastolic stiffness’.[32] 
The  diastolic  stiffness  of  the  left  ventricle  is  determined  by  the  pressure-volume 
relationship during diastole.  Increased LV stiffness results in resistance to changes in 
volume in response to rising filling pressure. 
The  most  common  cause  of  increased  LV  diastolic  stiffness  is  thought  to  be  LVH 
secondary  to  essential  hypertension.    Left  ventricular  hypertrophy  is  particularly 
common in patients with HF-PSF, strengthening the argument that LV diastolic stiffness 
is an important factor in the development of HF-PSF.[35]  The development of LVH is 
complex,  being  influenced  by  various  mechanical  and,  in  particular,  neurohumoral 
factors.[36,  37]    Left  ventricular  remodelling  and  hypertrophy  occur  in  response  to 
sustained elevation of pre-load or afterload in an attempt to maintain cardiac output.  
Ultimately these changes become maladaptive and deleterious to cardiac performance.  
There are two main pathophysiological processes in the development of LVH: myocyte 
hypertrophy and interstitial fibrosis.  Both of these phenomena can result in LV diastolic 
dysfunction.  Myocyte hypertrophy results in impaired active LV relaxation as described 
above.  Interstitial fibrosis is the increased deposition of myocardial extracellular matrix, 
in the form of collagen, through the proliferation and action of fibroblasts.  Interstitial 
fibrosis  results  in  a  poorly  compliant  LV  chamber  i.e.,  increased  LV  stiffness  and 
abnormal passive filling of the left ventricle during diastole.[38]   33 
 
1.4.4  Combined effects of abnormal relaxation and filling of the left ventricle 
The mechanisms by which impaired LV relaxation and increased LV stiffness result in 
diastolic dysfunction are illustrated in figure 1.2. 
 
Figure 1.2:  
Mechanism by which increased passive stiffness of the left ventricle and impaired active relaxation of the 
left ventricle combine to result in elevation of the left ventricular (LV) end-diastolic pressure.  Adapted 
from Gaasch WH, in Braunwald’s Heart Disease: a textbook of cardiovascular medicine.[1] 
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The end result of diastolic dysfunction is elevated LV diastolic pressure despite normal 
filling  volume.    Zile  et  al  employed  cardiac  catheterisation  to  obtain  invasive  LV 
pressure-volume  loops  from  patients  with  HF-PSF,  demonstrating  that  the  diastolic 
pressure rise is steeper per unit rise in volume that in subjects without HF-PSF (figure 
1.3).[39, 40]  
It is via this mechanism that diastolic dysfunction of the LV can lead to elevation of the 
LVEDP, left atrial hypertension, neurohumoral activation and the clinical features of 
heart failure.  Therefore, LV diastolic dysfunction is implicated in the pathophysiology 
of HF-PSF.   35 
Figure 1.3: 
Left ventricular pressure - volume relationship in patients with HF-PSF (diastolic heart failure) and normal 
subjects (controls) demonstrating the steep rise in intra-ventricular pressure with rising diastolic volume.  
Figure adapted from Zile et al 2002 and 2004.[39, 40] 
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1.4.5  Is HF-PSF purely due to LV diastolic dysfunction? 
The invasive cardiac catheter studies conducted by Zile et al [31] demonstrated that 
patients with HF-PSF have LV diastolic dysfunction, prompting the authors to suggest 
that formal assessment of diastolic dysfunction was unnecessary to make a diagnosis of 
‘diastolic  heart  failure’.    Although  HF-PSF  patients,  when  assessed  with  invasive 
studies,  have  LV  diastolic  dysfunction,  it  does  not  necessarily  follow  that  diastolic 
dysfunction will lead to the development of HF-PSF.  Other groups have examined 
diastolic  dysfunction  in  larger  populations  of  patients,  both  with  and  without  heart 
failure. Chen et al examined patients presenting with a first diagnosis of heart failure and 
found  that  only  half  of  patients  with  HF-PSF  had  echocardiographic  evidence  of 
diastolic dysfunction. [41]  
Petrie et al analysed echocardiograms of patients with a presumptive diagnosis of heart 
failure and found that there was poor correlation between echocardiographic markers of 
diastolic dysfunction and either the presence of heart failure or accepted risk factors for 
diastolic dysfunction, such as hypertension, LVH and myocardial ischaemia.[42]  Large 
cross-sectional population echocardiographic studies [43, 44] have shown that diastolic 
dysfunction is at least as common in men as in women but, as discussed in section 1.3, 
HF-PSF is much more common in elderly females. 
There are fundamental problems when comparing studies of LV diastolic dysfunction.  
Invasive assessment of LV function in all patients with suspected heart failure is not 
practical  and  echocardiographic  measures  of  diastolic  function  can  be  unreliable.  
Diastolic  properties  of  the  left  ventricle  are  load-dependent  and  therefore  prone  to   37 
variation even within the individual.[45] It is therefore difficult to be certain how much 
‘diastolic dysfunction’ is truly due to impaired active relaxation and/or increased passive 
stiffness of the left ventricle, and how much is influenced by pre-load conditions of the 
left ventricle.   
Although LV diastolic dysfunction certainly plays a role in the pathophysiology of HF-
PSF, the poor correlation between diastolic dysfunction and HF-PSF seen in population-
based studies has prompted consideration of other factors which may be implicated in 
the development of heart failure in this patient group. 
 
1.4.6  Ventriculo-vascular interaction 
Abnormal  vascular  function,  and  in  particular  the  interaction  between  the  systemic 
vasculature and the left ventricle, is a potential pathophysiological process in HF-PSF.  
Reduced aortic distensibility, or increased aortic impedance, has been known to increase 
LV afterload and adversely influence LV performance for more than 40 years.[46, 47]  
Since then, detailed studies of ventriculo-vascular interaction have been performed in 
both animal models and humans. Twenty years ago, Hori et al used a canine model to 
demonstrate that elevation of LV afterload during late systole directly impairs active LV 
relaxation  during  diastole.[48]  These  findings  have  been  confirmed  by  more  recent 
animal studies.[49] The possibility that late-systolic ventriculo-arterial interaction can 
adversely affect cardiac performance has been explored by other groups using human 
subjects.     38 
Ventriculo-vascular interaction and, in particular, ventricular and vascular stiffness are 
commonly described in terms of LV end-systolic elastance (Ees) and effective arterial 
elastance  (Ea),  as  discussed  by  David  Kass  in  his  2005  review  paper.[50]  Ea  is  a 
measure of arterial load derived from the ratio of LV end-systolic pressure to stroke 
volume.[51]  Ees  represents  the  LV  end-systolic  pressure-volume  relationship.  The 
Ea/Ees ratio is representative of end-systolic ventriculo-arterial interaction. Ea and Ees 
are  determined  by  invasively  or  non-invasively  measuring  the  LV  pressure-volume 
relationship throughout the cardiac cycle. An example of LV pressure-volume loops in 
young and elderly subjects, demonstrating Ea and Ees, is shown in figure 1.4.[52] 
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Figure 1.4: 
Pressure volume loops and relations derived by preload reduction maneuver in a young and in an elderly 
patient.  End  systolic  elastance  (Ees)  measures  chamber  systolic  stiffness  and  is  the  slope  of  a  line 
connecting  the  upper  left-hand  corners  (end  systole)  from  each  pressure  volume  loop  (dotted  line). 
Effective arterial elastance (Ea) measures arterial load and stiffness and is depicted by the negative slope 
of the diagonal solid line shown. Figure adapted from Chen et al 1998.[52] 
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Kass, Redfield and colleagues have conducted several studies investigating ventriculo-
vascular coupling in various patient groups, as detailed below. 
Redfield et al used non-invasive techniques to show that the combination of ventricular 
and  arterial  stiffening  is  more  common  in  elderly  females,[53]  the  section  of  the 
population most likely to develop HF-PSF according to population-based studies.[22, 
35, 41, 43]  Although subjects with diabetes or manifest cardiovascular disease were 
excluded  from  analysis,  almost  40%  of  the  subjects  were  taking  cardio-active 
medications,  which  could  have  influenced  the  results.  Chen  et  al  used  cardiac 
catheterisation to demonstrate that elderly subjects without heart failure have increased 
end-systolic LV and arterial stiffening.[52]  Once again, some aspects of the study group 
baseline characteristics are likely to have influenced the results.  The groups studied 
were  heterogeneous,  with  some  patients  having  severe  coronary  heart  disease  or 
significant hypertension, and a similar proportion having normal coronary arteries. 
These  investigators  have  also  conducted  studies  of  ventriculo-vascular  interaction  in 
patients with HF-PSF. Kawaguchi et al,[54] used a combination of invasive and non-
invasive methods to assess ventriculo-arterial interaction in HF-PSF.  Both ventricular 
and arterial stiffening were markedly elevated in subjects with HF-PSF, compared with 
both  young  and  age-matched  controls  without  cardiovascular  disease,  and  with  age-
matched subjects with hypertension.  Unfortunately the most interesting comparison, 
between HF-PSF and hypertensive subjects, was made using different methodologies. 
Subjects with HF-PSF underwent cardiac catheterisation and subjects with hypertension   41 
were assessed non-invasively with echocardiography.  Again, patients with coronary 
heart disease were excluded making the results less applicable to all patients with HF-
PSF. Melenovsky et al recruited subjects with HF-PSF, subjects with hypertensive LVH, 
and normal controls into their study.[55]  They examined multiple parameters of cardiac 
and  vascular  function  using  non-invasive  techniques.  The  study  population  was 
predominantly African-American females and there was a higher prevalence of coronary 
heart disease, renal dysfunction and diabetes mellitus in the HF-PSF group. They found 
that  HF-PSF  and  hypertension/LVH  groups  had  similar  abnormalities  of  ventriculo-
arterial stiffening and LV diastolic dysfunction but that LVH and left atrial dilatation 
were  more  marked  in  HF-PSF.  They  speculate  that  left  atrial  dysfunction  may  be 
involved in that pathophysiology of HF-PSF. Another important study from this group 
of investigators was reported by Lam et al.[56] A large cohort of patients with HF-PSF 
was recruited. Once again parameters of cardiac and vascular function were measured 
non-invasively  in  patients  with  HF-PSF  and  compared  to  hypertensives  and  normal 
controls. As in other studies, heterogeneity was present between groups: the HF-PSF 
patients  had  a  higher  prevalence  of  coronary  heart  disease  and  renal  dysfunction 
compared to both other groups and had significantly lower blood pressures than the 
hypertensive group. Despite this, Ea and Ees were similarly increased in HF-PSF and 
hypertensive patients, compared to controls. In contrast with the findings of Melenovsky 
et al, diastolic dysfunction was more severe in HF-PSF subjects. 
Another group who have investigated cardiac and vascular function in HF-PSF used 
cardiovascular magnetic resonance imaging to determine aortic stiffness and examined   42 
the correlation between aortic stiffness and exercise tolerance in HF-PSF. Hundley et al 
[57]  investigated  patients  with  HF-PSF  and  found  that  reduced  aortic  distensibility 
correlated  with  exercise  intolerance  in  their  cohort,  suggesting  that  reduced  arterial 
compliance, and therefore elevated LV afterload, is implicated in the development of 
symptoms in HF-PSF.  The patient selection process was robust, with clearly defined 
criteria to diagnose HF-PSF.  However, subjects in the control group were normotensive 
and  free  of  cardiovascular  disease,  which  undoubtedly  enhanced  the  differences  in 
vascular and ventricular abnormalities observed between HF-PSF and control groups.  In 
addition, patients with coronary heart disease were excluded and this may have led to an 
atypical cohort of patients with HF-PSF being studied.  The same investigators have 
since published a similar study conducted in patients with HF-RSF.[58]  They found that 
HF-RSF is also associated with reduced aortic distensibility and exercise intolerance.  
One  could  conclude  from  these  two  studies  that  reduced  large  artery  compliance 
adversely influences LV performance and therefore symptoms, regardless of LV systolic 
function.  Whether or not reduced arterial compliance causes HF-PSF is as yet unproven. 
The role of abnormal ventricular-arterial interaction in the pathophysiology of HF-PSF 
has yet to be fully established.  Even so, the evidence presented by the above studies has 
cast doubt on the theory that HF-PSF is purely a disorder of LV diastolic function, with 
more  than  one  group  suggesting  that  the  pathophysiology  is  in  fact  far  more 
complex.[59, 60]  The combination of ventricular stiffening and increased LV afterload 
has many implications when considering the pathophysiology of HF-PSF.  Increased 
afterload increases cardiac work and oxygen requirements.  Combined ventricular and   43 
arterial stiffening results in labile haemodynamic responses to both exercise and changes 
in  circulating  volume.    Elevation  of  LV  afterload  is  a  powerful  stimulus  for  the 
development of LVH, which, as described in section 1.4.3, causes increased passive 
stiffness of the left ventricle during diastole. 
Left ventricular chamber stiffness, diastolic dysfunction and afterload are closely linked 
via dynamic interaction and may all be implicated in the pathophysiology of HF-PSF.  
 
1.5  Vascular Function 
 
There  are  reasons  to  believe  that  vascular  dysfunction  is  implicated  in  the 
pathophysiology of HF-PSF.  Arterial stiffness is the main determinant of LV afterload 
and  influences  ventriculo-vascular  coupling.    Some  groups  have  investigated  arterial 
compliance in HF-PSF but overall very little is known about vascular function in HF-
PSF.  Control of arterial tone via arterial endothelial and smooth muscle function is 
likely to influence arterial stiffness and compliance, but has never been investigated in 
HF-PSF.  Venous capacitance and control of venous tone are important determinants of 
LV preloading conditions that, if abnormal, could theoretically contribute to increased 
LVEDP and the clinical syndrome of heart failure.  As with arterial endothelial and 
smooth muscle function, venous function has never been studied in HF-PSF. 
Vascular  function  (and  dysfunction)  is  dynamic  and  complex.    There  are  multiple 
methods available to assess vascular function.  In the following section, I will provide an   44 
overview  of  the  aspects  of  vascular  dysfunction  that  I  feel  are  most  relevant  to  the 
pathophysiology  of  HF-PSF.    I  will  discuss  the  concept,  clinical  relevance  and 
assessment methods of: arterial stiffness and compliance; arterial endothelial and smooth 
muscle function; venous capacitance; and venous endothelial function. 
 
1.5.1  Arterial stiffness and arterial compliance 
The  terms  arterial  stiffness  and  arterial  compliance  are  often  used  to  describe  the 
properties of the arterial tree.  It is a common belief that these terms are interchangeable, 
but they are actually slightly different.  As outlined in the preceding section, arterial 
stiffening  may  have  an  important  role  to  play  in  the  pathophysiology  of  HF-PSF.  
Arterial stiffening is an all-encompassing term used to describe rigidity of the arterial 
tree.  To understand pathological arterial stiffening, one must first appreciate the main 
mechanisms  affecting  blood  flow  through  the  arterial  tree,  one  of  which  is  arterial 
compliance. 
The term ‘arterial compliance’ refers to the ability of large arteries, namely the aorta and 
its major branches, to distend in response to a given pressure.  The aorta and major 
branches  act  as  an  elastic  reservoir,  buffering  pulsatile  flow  from  LV  ejection,  and 
transmitting  less-pulsatile  flow  to  the  peripheral  vasculature.    This  is  known  as 
windkessel theory. 
The windkessel model of the circulation was originally proposed by Hales in 1733 [61] 
and further developed by Frank in 1899.[62]  An analogy was made between the hand-
operated fire-fighter water pump (windkessel in German) and the relationship between   45 
the left ventricle, aorta and conduit vessels.  The pump was primed with intermittent air 
injections.  When the air pressure within the pump reached a certain level, a steady 
stream of water was forced out.  Windkessel theory compares this sequence of events 
with the buffering action of the aorta, receiving pulsatile flow from the left ventricle and 
delivering relatively steady flow to the conduit vessels.  This analogy enhanced early 
understanding of blood flow through the arterial tree.[63]  Although windkessel theory 
helps to understand the importance of elastic and conduit characteristics of arteries, this 
model of the circulation assumes that the arterial tree has separate elastic and conduit 
compartments.  In fact most of the arterial tree has both elastic and conduit properties, 
although one or other tends to predominate in any given arterial segment.  For example, 
the ascending aorta is predominantly elastic and the peripheral, more muscular, arteries 
are predominantly conduit vessels.  
 
1.5.2  Propagation of the arterial pressure wave 
The second mechanism is propagation of the arterial pressure wave through the arterial 
tree.  The speed at which the arterial pressure wave is transmitted is termed the pulse 
wave velocity.  Young originally described the relationship between PWV and stiffness 
of  the  vessel  wall  in  1804.  The  concept  was  developed  in  the  first  half  of  the  20
th 
Century when work by Frank in 1920 [64] and then Bramwell and Hill in 1922 [65] led 
to development of the Moens-Korteweg equation:  
PWV=   h/2R   • inc E    46 
(Where  Einc  is  Young’s  Modulus  of  the  arterial  wall,  h is  wall  thickness,  R  is  end-
diastolic radius and ρ is blood density). 
The velocity of the pulse wave is inversely proportional to the elasticity of the vessel 
wall.  Pulse wave velocity may be measured by recording the pulse wave at a proximal 
and  distal  artery  (e.g.  carotid  and  femoral),  either  simultaneously  or  gated  to  the 
electrocardiogram  (ECG),  using  pressure  transducers,  Doppler  ultrasound  probes  or 
applanantion tonometry.[66] The distance travelled is determined by measuring the body 
surface  distance  between  the  proximal  and  distal  arterial  points.    The  resulting 
calculation gives a direct measure of arterial stiffness that is easily reproducible.[67, 68] 
 
 
1.5.3  Arterial pressure wave reflection and diastolic waveform analysis 
The arterial pressure waveform is a composite of incident and reflected waves.  Wave 
reflection occurs at points of impedance mismatch, such as vessel bifurcation and is also 
influenced by the diameter and contractile properties of the resistance arterial bed.[69]  
The point at which the reflected wave returns to the proximal aorta is dependent upon 
the speed with which the incident wave travels along the aorta, i.e. the PWV.  In health 
the  reflected  wave  arrives  in  the  proximal  aorta  in  diastole,  augmenting  diastolic 
pressure and facilitating coronary artery flow.  When, as a result of arterial stiffening, 
PWV increases, the reflected wave may arrive earlier, in systole.  The reflected wave 
superimposes on the incident systolic wave, augmenting systolic blood pressure.  This 
early return of the reflected wave during systole results in a steepening of the diastolic   47 
decay contour of the pressure waveform, reduced diastolic blood pressure and widening 
of the pulse pressure.[70] The proportion of this augmented pulse pressure that results 
from wave reflection is termed the augmentation index (AIx). Therefore, aortic PWV, 
peripheral  wave  reflection  from  resistance  arteries  and  pulse  pressure  are  directly 
related. An example of the central aortic waveform is shown in figure 1.5. 
Figure 1.5: 
The central (aortic) pressure waveform consists of an incident wave, generated by systolic left ventricular 
ejection, and a reflected wave, from impedance points of the peripheral arterial tree. Haemodynamic 
parameters are derived by analysis of the central aortic pressure wave. T0 indicates the time at the start of 
the waveform; T1, duration from start of waveform to the first peak/shoulder (incident pressure wave); T2, 
duration from start of waveform to the second peak/shoulder (reflected pressure wave); ED, ejection 
duration, or duration from start of waveform to closure of the aortic valve (incisura); SP, central aortic 
systolic pressure; DP, central aortic diastolic pressure; P1, P1 height difference between the minimum 
pressure and the pressure at the first peak/shoulder (T1); augmentation (P), difference between maximal 
pressure (central aortic systolic pressure) and pressure at the fist peak/shoulder (P1 height); PP, pulse 
pressure; and AIx, augmentation index. Figure from Williams et al, 2006.[71] 
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In an attempt to characterise the properties of resistance vessels, i.e. points of impedance 
mismatch  and  wave  reflection,  more  advanced  models  of  the  circulation  have  been 
developed.    Initial  work  by  Hales  and  Frank  [61,  62]  on  windkessel  models  of  the 
circulation  provided  the  building  blocks  for  development  of  these  more  advanced 
models. 
Flow within a blood vessel is determined by two factors: 1) the difference in pressure 
between both ends of the vessel, i.e. the pressure gradient forcing blood through the 
vessel; and 2) the resistance of the vessel to flow.  In a two-element windkessel model, 
these two factors are described in terms of an electrical circuit, as a resistor and an 
inductor.  The human circulatory system is clearly far more complex than a simple two-
element model, and the concept was developed accordingly.  A third-order windkessel 
model  was  proposed  by  Watt  et  al  in  1976  [72]  and  includes  two  capacitors  in  the 
circuit, representing the total compliance of proximal large arteries, and distal small 
arteries, termed C1 and C2, respectively. 
Cohn and colleagues combined this electrical analogy of the circulation with analysis of 
the arterial pressure waveform, in particular the diastolic portion of the waveform.  They 
analysed the diastolic waveform in terms of two components. 1) Diastolic decay of the 
incident wave representing elastic recoil of the proximal, large arteries.  This is termed 
capacitive compliance, or C1. 2) Fluctuations of the diastolic waveform due to reflected 
waves from small, peripheral resistance vessels.  This is termed oscillatory compliance, 
or C2 (figure 1.6).[73] 
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Figure 1.6: 
Modified windkessel model used for analysis of vascular properties. C1 indicates capacitive compliance; 
C2, oscillatory compliance; R, systemic vascular resistance; L, inertia of the blood; P1, proximal pressure; 
and P2, distal pressure.  Figure adapted from Cohn J et al, 1995.[73] 
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1.5.4  Clinical significance of arterial stiffness 
There are many factors that affect arterial stiffness in vivo.  The proportion of elastin to 
collagen fibres in the vessel wall is extremely important, with the number and integrity 
of elastin fibres being closely related to the elastic properties of the aorta and major 
branches.[74]  Another  factor  which  must  be  considered  when  evaluating  arterial 
stiffness is the distending pressure of blood within the vessel lumen. With increasing 
pressure,  there  is  increased  recruitment  of  less  elastic  collagen  fibres  in  the  vessel 
wall.[75] Therefore, increased distending pressure, for example in systolic hypertension, 
results in increased arterial stiffness through two mechanisms: 1) increased distending 
intra-luminal pressure; and 2) arterial remodelling, with thinning and fragmentation of 
elastin  fibres,  which  are  eventually  replaced  by  collagen,  fibrosis  and  in  advanced 
stages,  calcification.[76,  77]    This  process  results  in  a  positive  feedback  loop  of 
increased pressure resulting in increased stiffness from vessel distension and  arterial 
remodeling,  elevation  of  PWV,  early  return  of  reflected  pressure  waves,  further 
augmentation of systolic pressure and vascular damage (figure 1.7).[70] 
Other important influences on arterial stiffness include the bulk and tone of smooth 
muscle in the vessel wall, the latter being partly controlled by endothelium [78] and 
neurohumoral factors.[79]  As the body ages, the aorta undergoes significant structural 
change.  With increasing age, there is a linear relationship with elevation of the systolic 
blood pressure in association with reduction of the diastolic blood pressure and widening 
of the pulse pressure.[80]  Pulse pressure is related to the development of surrogate 
markers of cardiovascular risk, such as LVH.[81]  Pulse pressure itself is an independent   51 
predictor of cardiac events, as evidenced by data from the Framingham study [82, 83] 
and from large longitudinal studies in France [84] and Germany.[85] As with PWV, 
pulse pressure rises with age [80] and is an important factor in the development and 
clinical course of cardiovascular diseases, including heart failure.[86-88] A landmark 
study comparing pulsatile haemodynamics non-invasively between patients with HF-
RSF and controls without heart failure, was performed by Mitchell et al.[89] This study 
demonstrated that patients with HF-RSF have both wider pulse pressure and increased 
characteristic aortic impedance (termed Zc – a  measure of proximal aortic stiffness) 
compared  to  controls,  indicating  that  properties  of  the  arterial  tree  are  likely  to  be 
implicated in the pathophysiology of heart failure.  
Perhaps unsurprisingly, PWV has also been shown to be an independent predictor of 
cardiovascular  risk.    Blacher  et  al  demonstrated  that  elevated  PWV  predicts 
cardiovascular  mortality  in  patients  with  end-stage  renal  disease.[90]    Pulse  wave 
velocity also predicts cardiovascular events in those with traditional cardiovascular risk 
factors, such as patients with hypertension,[91] diabetes,[92] and in subjects over 70 
years of age.[93] 
Analysis of diastolic pressure waveforms has  shown that diabetes is associated with 
abnormal peripheral arterial function,[94] and that elderly subjects display abnormalities 
of both central and peripheral arterial function.[95]  There are, as yet, no data on the 
ability of diastolic pressure waveform analysis to predict cardiovascular outcomes.   52 
Figure 1.7: 
Positive feedback loop indicating the pathogenesis of arterial stiffness. Figure adapted from Dart AM, 
Kingwell BA, 2001.[70] 
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1.5.5  Assessment of arterial stiffness 
There are many ways of assessing arterial stiffness in vivo, both invasively and non-
invasively.  In recent years there has been much interest in the non-invasive assessment 
of arterial function, particularly in view of the risks to patients associated with invasive 
instrumentation.    Non-invasive  assessment  of  arterial  stiffness  lends  itself  to  a  wide 
range of uses in the research arena, and there has been a large amount of literature 
published in this area, as reviewed by Oliver and Webb.[96]  In a joint venture of the 
European  Society  of  Cardiology  and  the  European  Society  of  Hypertension,  the 
European Network for Non-invasive Assessment of Large Arteries was formed and has 
reviewed  methods  currently  used  to  assess  arterial  stiffness  non-invasively,  deeming 
carotid-femoral PWV to be the ‘gold standard’ method.[67]  In view of the correlation 
between increased arterial stiffness and increased risk of cardiovascular events, non-
invasive assessment of arterial stiffness is gathering momentum as a means of estimating 
cardiovascular risk in the clinical setting. 
 
1.5.6  Arterial endothelial function – relevance to heart failure 
As demonstrated nearly 40 years ago by Zelis et al [97] patients with heart failure have 
impaired peripheral vasodilatation in response to various stimuli.  Over the years, it has 
become  apparent  that  arterial  endothelial  dysfunction  plays  an  important  role  in  the 
attenuation of peripheral vasodilatation observed in heart failure patients.[78] Arterial 
endothelial dysfunction has been well documented in HF-RSF [98-102] and is due to 
multiple  factors,  including  maladaptive  overactivity  of  the  RAAS  system,[79]   54 
circulating endothelin [103] and oxidant stress.[18, 104, 105]  The vascular endothelium 
is integral to maintaining normal vessel tone  and function and, therefore, influences 
arterial  stiffness.[76]    It  could  be  argued  that  abnormal  arterial  endothelial  function 
increases arterial stiffness and may adversely affect ventriculo-vascular interaction: a 
probable key factor in the pathophysiology of HF-PSF.  Impaired arterial endothelial 
function is associated with reduced arterial compliance in older individuals,[106] which 
may be relevant in patients with HF-PSF who tend to be elderly.  However, no such 
studies have been performed in subjects with HF-PSF and whether or not HF-PSF is 
associated with arterial endothelial dysfunction is not known.  
 
1.5.7  Methods of assessing arterial endothelial function 
There are several methods available for the assessment of arterial endothelial function.  
Much of our original information about vascular function, including the role of arterial 
endothelial function, was obtained with in vitro (or ex vivo) studies of blood vessels 
mounted on strain gauges and exposed to vasoactive agents.  This method was used to 
demonstrate  that  vascular  endothelium  plays  a  role  in  vasodilatation  [107]  and  that 
endothelium-derived  relaxing  factor,  later  proven  to  be  nitric  oxide,  is  the  key 
endogenous  vasodilating  agent  released  by  vascular  endothelium.[108]  A  related 
method,  termed  wire  myography,  has  been  used  more  recently  using  human  vessels 
taken  from  patients  with  cardiovascular  diseases,  such  as  heart  failure  and  coronary 
artery disease.[109]   55 
In  vivo  studies  of  vascular  function  obviously  have  the  advantage  of  providing 
information  on  ‘real  life’  arterial  endothelial  function  in  the  context  of  the  disease 
process under investigation. 
The most widely used technique involves cannulation of the brachial artery and intra-
arterial  infusion  of  vasoactive  agents,  most  commonly  the  endothelial-dependent 
vasodilator  acetylcholine  and  the  endothelial-independent  vasodilator  sodium 
nitroprusside,  combined  with  forearm  venous  occlusion  plethysmography  to  assess 
changes in forearm blood flow.[100-102, 110] 
An alternative method of measuring changes in forearm blood flow is referred to as 
flow-mediated dilatation. Flow-mediated dilatation can be measured with a variety of 
techniques, one of the commonest being high fidelity ultrasound of the brachial or radial 
artery.  Changes in diameter of the forearm resistance arteries correspond closely to 
forearm  blood  flow.    This  technique  can  be  used  with  post-ischaemic  reactive 
hyperaemia, which is predominantly influenced by arterial endothelial function,[99] or 
with  intra-brachial  infusions  of  endothelium-dependent  and  –independent 
vasodilators.[111] 
Another non-invasive method of assessing endothelial function involves administering 
vasoactive  agents,  typically  acetylcholine  and  sodium  nitroprusside,  to  the 
microvasculature of the skin using low voltage electrical current.  This method of drug 
delivery  is  known  as  iontophoresis.    The  corresponding  vasodilatory  effect  is  then 
measured with Laser Doppler imaging, with increased flow of red blood cells during 
vasodilation  giving  higher  intensity  Laser  Doppler  readings,  or  ‘flux’.[112]  In  the   56 
literature this technique of measuring microvascular responses to vasoactive agents is 
termed ‘Laser Doppler iontophoresis’, ‘Laser Doppler fluximetry’ or ‘Laser Doppler 
flowmetry’ and has been used to assess microvascular endothelial function in patients 
with HF-RSF [113] and in patients with various cardiovascular risk factors.[114-116]  
Laser  Doppler  iontophoresis  has  been  shown  to  be  reproducible  [117]  and  results 
correlate  well  with  those  obtained  by  alternative  methods  of  measuring  arterial 
endothelial function, such as wire myography [118] and flow-mediated dilatation.[116, 
119] 
 
1.5.8  Venous capacitance 
The venous system has been studied far less than the arterial system in cardiovascular 
research.  As a result, there is limited information on the role of the venous system in 
cardiovascular  disease.    The  venous  system  is  best  described  in  terms  of  pressure-
volume relationships. 
Venous capacitance refers to the ability of the venous bed to increase in volume in 
response to pressure.  Venous capacitance is predominantly influenced by two factors: 
1) Intra-luminal venous pressure and the corresponding effect on vessel wall tension.  
Veins are thin-walled and extremely distensible at low pressures.  However, at the peak 
of the pressure-volume curve veins become less compliant and the curve plateaus out 
(figure 1.8).[120]   57 
2) Changes in venous tone.  Venous tone is actively controlled by mural smooth muscle, 
which in turn is influenced by venous endothelium.  These mechanisms are discussed in 
more detail in section 1.5.10. 
Most  of  the  circulating  volume  lies  in  the  venous  bed,  which  acts  as  a  capacitance 
reservoir.    Changes  in  venous  capacitance  can  have  dramatic  effects  on  LV  filling 
pressure, or pre-load, and stroke volume.[121]   
Assessment  of  venous  capacitance  has  predominantly  been  performed  by  measuring 
changes in either upper or lower limb volume in response to occluding venous return 
from the limb.  The assumption being that changes in volume will be attributable to 
venous distension and pooling, as bone and muscle have a relatively constant volume at 
rest. 
This investigative technique is termed venous occlusion plethysmography.  Essentially, 
circumferential changes in limb circumference during venous congestion are measured 
and pressure/volume data is extrapolated to give a measurement of venous capacitance.  
The basic principles of performing venous occlusion plethysmography in the limbs were 
first described by Hewlett and van Zwaluwenburg in 1909 [122] and have become more 
sophisticated over time.  Changes in limb circumference were originally recorded using 
a fluid-filled cuff to enclose the whole forearm.  The rise in forearm volume caused 
deflection of a column of water that was then measured.  In the late 1940’s, a mercury-
filled  rubber  gauge  was  developed  to measure  changes  in  limb  circumference.   The 
gauge forms part of a constant current electrical circuit and will provide a recordable   58 
linear output that responds to tension on the gauge.  This technique was introduced by 
Whitney [123] and further developed by Hokanson and colleagues.[124] 
More recently, radionuclide plethysmography has been developed.  Although technically 
more challenging, radionuclide plethysmography facilitates the assessment of multiple 
vascular beds, such as pulmonary and splanchnic, in addition to the vasculature of the 
upper and lower limbs.[120] 
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Figure 1.8: 
Relationship between trans-mural pressure and volume in veins, demonstrating marked compliance at low 
pressure  but  relatively  low  compliance  at  higher  pressures.  Figure  adapted  from  Schmitt  M  et  al, 
2002.[120]
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1.5.9  Venous capacitance – relevance to heart failure 
Venous  capacitance  has  been  studied  in  the  context  of  HF-RSF.    Reduced  venous 
capacitance is associated with reduced exercise capacity in patients with HF-RSF.[125]  
Reduced venous capacitance has also been demonstrated to correlate with more severe 
symptoms of heart failure and elevated pulmonary artery pressure in patients with HF-
RSF.[126]  There are also data, from canine models of heart failure, to suggest that 
reduced LVEF can induce marked baroceptor-mediated venoconstriction resulting in a 
dramatic increase in LVEDP.[127]  Frenneaux’s group have completed multiple studies 
using radionuclide plethysmography to assess venous function in patients with HF-RSF 
and  in  normal  subjects.    They  have  demonstrated  that  venous  capacitance  responds 
appropriately  to  endothelial-dependent  vasodilatation,  despite  evidence  of  impaired 
arterial endothelial function.[98]  Their data also show that venous capacitance is under 
the control of natriuretic peptides both in patients with HF-RSF [128] and in healthy 
subjects,[129] but that exogenous aldosterone has little effect on venous capacitance in 
HF-RSF.[130] 
Reduced venous capacitance may also play an important role in the pathophysiology of 
HF-PSF.  Patients with HF-PSF are more sensitive to the effects of vasodilators and 
diuretics on LV filling pressure, suggesting that venous capacitance is reduced.[131, 
132]    Although  there  is  evidence  to  support  the  theory  that  changes  in  venous 
capacitance can influence both symptoms and LVEDP in HF-RSF, there have been no 
studies of venous capacitance in patients with HF-PSF.   
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1.5.10  Venous endothelial function 
The most accurate method of assessing venous endothelial function is with the dorsal 
hand vein technique, introduced by Nachev, Collier and Robinson in 1971 [133] and 
modified by Aellig ten years later.[134] 
This  technique  involves  placing  a  sensor,  attached  to  a  linear  variable  transformer, 
directly  over  a  dorsal  hand  vein.    The  vein  is  then  cannulated  to  allow  vasoactive 
substances to be administered locally.  The venous return from the limb is occluded 
intermittently and compliance of the vein during venous congestion is measured.  In this 
manner, the effects of vasoactive drugs on venous compliance can be assessed in real 
time.[135,  136]    By  using  endothelium-dependent  and  –independent  vasodilators,  a 
measure  of  venous  endothelial  and  vascular  smooth  muscle  function  can  be 
derived.[137]  Most studies using the dorsal hand vein technique have been carried out 
in healthy adults.  Some of these studies have focused on the effects of vasoactive agents 
which are potentially important in the pathophysiology of HF-RSF, such as angiotensin I 
and II,[138] endothelin,[139] atrial natriuretic peptide [140] and norepinephrine.[141]   
A few groups have performed dorsal hand vein studies in patients with HF-RSF.  Love 
et al characterised the venoconstrictive effects of endothelin receptor agonists in patients 
with HF-RSF.[142]  Dzeka et al demonstrated that patients with HF-RSF have venous 
endothelial dysfunction and an exaggerated venoconstriction response to prostaglandin 
inhibition.[143]    It  has  also  been  shown  that  HF-RSF  patients  display  marked 
venoconstriction  in  response  to  neuropeptide  Y,  a  sympathetic  neurotransmitter,  in 
comparison with healthy controls.[144]   62 
The  venous  endothelium  plays  an  important  role  in  maintaining  venous  tone  and, 
therefore,  modulates  venous  capacitance.    Previous  studies  suggest  that  HF-RSF  is 
associated  with  venous  endothelial  dysfunction.    The  venous  endothelium  has  never 
been studied in patients HF-PSF and therefore it is not known whether or not venous 
endothelial dysfunction plays a role in the pathophysiology of HF-PSF. 
The  interaction  of  the  vascular  system  with  the  heart  is  dynamic  and  complex.  
Abnormal  vascular  function,  and  increased  arterial  stiffness  in  particular,  has  been 
shown to adversely affect left ventricular morphology and function, for example the 
development of LVH in systolic hypertension.  As LVH and LV diastolic dysfunction 
have been associated with HF-PSF, it is possible that abnormal vascular function leads 
to  the  development  of  HF-PSF.    However,  the  role  of  vascular  dysfunction  in  the 
pathophysiology of HF-PSF has not yet been established. 
 
1.6  Summary 
 
Heart  failure  is  a  clinical  syndrome  that  can  occur  in  the  presence  of  reduced  or 
preserved LV systolic function.  The investigation of the pathophysiology of HF-PSF to 
date has answered some questions about potential mechanisms involved but the subject 
remains an area of controversy and debate.  From reviewing the evidence available, 
diastolic dysfunction of the left ventricle appears to play a key role in the development 
of heart failure in these patients, as HF-PSF subjects usually have abnormalities of LV   63 
relaxation and filling on invasive assessment.[39]  However, the idea that HF-PSF is 
purely due to diastolic dysfunction has been challenged.  The main basis for questioning 
the ‘diastolic heart failure’ theory is that parameters of diastolic function vary widely 
depending on loading circumstances of the left ventricle and do not always correlate 
with presence of heart failure in population-based studies.[42] 
An  alternative  theory  is  that  impaired  vascular  function  adversely  affects  LV 
performance and ultimately leads to development of the heart failure syndrome. 
There are some data to support the hypothesis that HF-PSF is causally associated with 
impaired  ventriculo-arterial  interaction:  both  increased  stiffness  of  the  left  ventricle 
during  systole  and  reduced  arterial  compliance  have  been  demonstrated  in  previous 
studies.[54, 57] These results are perhaps not surprising, given that LV afterload, i.e. 
large  artery  compliance,  has  long  been  accepted  as  a  determinant  of  LV  mass  and 
systolic and diastolic performance (section 1.4). 
I propose that the role of vascular function in the pathophysiology of HF-PSF has not yet 
been fully established.  Previous studies have suggested that reduced arterial compliance 
is frequently present in patients with HF-PSF, but the groups included for study have 
been  heterogeneous,  with  a  high  percentage  of  patients  having  significant  co-
morbidities.  Co-morbidities varied between groups compared and conditions which are 
known to be associated with reduced arterial compliance, such as diabetes mellitus and 
coronary heart disease, were not matched for during patient selection.  Concomitant 
medications were also extremely variable between groups, which may have confounded 
results from previous studies.  Furthermore, vascular function in HF-PSF and HF-RSF   64 
has  not  been  directly  compared.    It  is  therefore  uncertain  whether  or  not  vascular 
dysfunction is secondary to the ‘heart failure syndrome’, with compensatory activation 
of  neurohumoral  and  inflammatory  systems  resulting  in  abnormalities  of  vascular 
function and tone, or if vascular dysfunction is a primary pathophysiological mechanism 
in the development of HF-PSF.  There are other unanswered questions regarding the role 
of the vasculature in the pathophysiology of HF-PSF.  Mechanisms controlling arterial 
tone  and  function,  such  as  endothelium  and  smooth  muscle,  have  been  extensively 
investigated in HF-RSF, but have never been evaluated in HF-PSF.  Most investigators 
of heart failure pathophysiology have neglected to study the venous bed.  Although there 
are  some  data  on  venous  function  in  HF-RSF,  venous  capacitance  has  not  been 
examined in HF-PSF and may be important in determining LV preload conditions.  To 
date, nothing is known about endothelial control of venous tone in HF-PSF.   
My hypothesis is that abnormalities of vascular function are more extensive and severe 
in HF-PSF than in HF-RSF, supporting the theory that vascular dysfunction plays a key 
role in the complex pathophysiology of HF-PSF.  The studies described in this thesis 
were designed to test this hypothesis. 
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Chapter 2 
 
Materials and Methods 
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2.1  Patient Selection 
 
This project conforms to the principles outlined in the Declaration of Helsinki and was 
approved by the West Medical Ethics Committee, Western Infirmary, Glasgow, UK.  
All patients gave written, informed consent. 
 
2.1.1  Study groups 
Three groups of patients were recruited: 
HF-PSF group 
Patients with coronary heart disease and HF-PSF. 
HF-RSF group 
Patients with coronary heart disease and HF-RSF. 
Control group 
Patients with coronary heart disease, preserved LV systolic function, and no evidence of 
heart failure. 
 
2.1.2  Definitions and inclusion criteria 
Heart failure was defined as:  
a) Relevant symptoms/ signs/ radiographic findings as indicated by Boston criteria (table 
2.1).[4] 
b) Clinical requirement for diuretic therapy    67 
c)  Increased  plasma  N-terminal  pro  b-type  natriuretic  peptide  (NT-proBNP) 
concentration (section 2.2.8).  
Subjects had to fulfill all three criteria to be included in either heart failure group. 
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Table 2.1: 
Boston criteria for diagnosis of heart failure. Each parameter has a corresponding score. 
Scores are added to give a total.  If the total Boston score > 8, the diagnosis of heart 
failure is deemed probable. JVP: jugular venous pressure; PA: postero-anterior. 
 
 
 
CRITERION 
 
History 
 
Rest dyspnoea 
Orthopnoea 
Paroxysmal nocturnal dyspnoea 
Dyspnoea walking on flat 
Dyspnoea walking on incline 
 
Examination 
 
Pulse 91-110bpm 
Pulse > 110bpm 
JVP > 6cm 
JVP > 6cm + hepatomegaly or peripheral edema 
Rales – basilar 
Rales – basilar and elsewhere 
Wheeze 
Third heart sound 
 
Chest Radiograph 
 
Alveolar oedema 
Interstitial oedema 
Bilateral effusions 
Cardiothoracic ratio > 50% (PA film) 
Upper lobe venous diversion 
 
 
 
SCORE (if present) 
 
 
 
4 
4 
3 
2 
1 
 
 
 
1 
2 
2 
3 
1 
2 
3 
3 
 
 
 
4 
3 
3 
3 
2 
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Echocardiographic parameters: 
a) Preserved LV systolic function was defined as: 
LVEF of ≥0.50, measured by echocardiography.   
b) Reduced LV systolic function was defined as: 
LVEF of < 0.40, measured by echocardiography. 
Echocardiograms  were  performed  by  a  single  operator,  who  was  blinded  to  subject 
group allocation, on a routine basis for clinical reasons in all subjects. Left ventricular 
ejection  fraction  was  calculated  using  semi-quantitative  assessment  with  16  segment 
wall motion scoring.[145] 
 
Coronary heart disease was defined as: 
a) Previous myocardial infarction. 
AND/OR 
b)  Symptoms  of  angina  pectoris  with  exercise  electrocardiogram  or  myocardial 
perfusion scan evidence of reversible myocardial ischaemia. 
AND/OR 
c) Evidence of significant coronary artery disease at coronary angiography. 
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2.1.3  Exclusion criteria 
a) Significant valvular heart disease (defined as at least moderate dysfunction of one or 
more heart valves at echocardiography). 
b) Atrial fibrillation. 
c) Diabetes mellitus. 
d) Renal failure (defined as serum creatinine  >250µmol/L). 
e)  Uncontrolled  hypertension  despite  antihypertensive  therapy  (systolic  BP  >140  or 
diastolic BP >90mmHg). 
 
2.1.4  Screening process 
All emergency admissions to the Western Infirmary Glasgow with a primary diagnosis 
of  heart  failure,  admitted  between  August  2003  and  June  2005,  were  screened  for 
potential enrolment in the study. 
The  central  database  comprising  all  attendees  of  the  Heart  Function  Clinic  at  the 
Western Infirmary was screened for patients who could potentially be recruited into the 
study. 
In order to be eligible for the study patients had to be able and willing to undertake two 
whole mornings of vascular function studies.  Recruitment of subjects into the HF-PSF 
group was therefore slow as a high proportion of the patients were elderly, with multiple 
co-morbidities, and thus unsuitable.  A significant number of patients with HF-PSF also 
had specific exclusions such as diabetes mellitus or atrial fibrillation.   71 
To speed up recruitment into the HF-PSF group I incorporated twice-weekly review of 
the  echocardiography  laboratory  log  at  the  Western  Infirmary  into  my  screening 
methods.  All patients whose indication for echocardiography was heart failure and who 
had  preserved  LV  systolic  function  were  screened  for  potential  recruitment  into  the 
study. 
In total 935 patients were considered for recruitment into the HF-PSF group.  Of these 
935 patients, 803 were excluded.  The commonest reason for exclusion was inadequate 
objective  evidence  of  heart  failure  to  achieve  a  Boston  score  of  >8.    The  second 
commonest  reason  for  exclusion  was  the  presence  of  multiple  co-morbidities  and/or 
general  frailty,  making  it  impractical  for  patients  to  undergo  two  full  mornings  of 
vascular function studies.  The remaining exclusions were on the basis of pre-defined 
exclusion criteria, most frequently diabetes mellitus or atrial fibrillation.  Of the 132 
patients  who  were  suitable  for  recruitment  into  the  HF-PSF  group,  112  declined  to 
participate.  8 patients agreed to participate after initial invitation but later cancelled or 
did not attend for vascular function studies.  Therefore, 12 patients were successfully 
recruited into the HF-PSF group. 
Control  subjects  and  HF-RSF  subjects  were  identified  and  recruited  by  screening 
patients  attending  general  cardiology  and  Heart  Function  clinics  at  the  Western 
Infirmary. 
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2.2  Study Design 
 
This  study  was  conducted  in  the  Clinical  Investigation  and  Research  Unit  (CIRU), 
Gardiner Institute, Western Infirmary, Glasgow, UK.  Subjects attended the CIRU on 
two occasions in the morning following a light breakfast. Subjects were asked to abstain 
from caffeine and tobacco for 12 hours and to omit their morning medication prior to 
their visit. 
 
2.2.1  Schedule of experiments 
First visit 
The experimental protocol was as follows: 
1)  An equilibration period of 30 minutes supine rest in a temperature-controlled (21-
23
oC) vascular study room. 
2)  Applanation tonometry: carotid-femoral (aortic) PWV. 
3)  Applanation tonometry: radial arterial diastolic waveform analysis.  This experiment 
includes heart rate and brachial blood pressure measurement. 
4) Laser Doppler iontophoresis. 
5) Venous occlusion plethysmography. 
Second visit 
1) Equilibration period of 30 minutes supine rest in a temperature-controlled (21-23
oC) 
vascular study room.   73 
2) Aellig dorsal hand vein study.  
3) Venepuncture for NT-proBNP, renal biochemistry and total cholesterol. 
Both visits were conducted under identical conditions, as described above, one week 
apart. 
The duration of the first visit was approximately 4 hours and the duration of the second 
visit  was  between  3  and  4  hours.    Offline  processing  of  raw  data  combined  with 
subsequent  statistical  analysis  took  between  12  and  13  hours  per  patient  studied.  
Therefore the total time to perform vascular function studies including processing and 
analysing the data was between 19 and 21 hours per patient. 
 
2.2.2  Aortic pulse wave velocity 
Aortic pulse wave velocity (PWV) was measured using a high fidelity micromanometer 
(SPC-301; Millar Instruments, Texas, USA) coupled with the SphygmoCor™ system 
(SphygmoCor™ BPAS; PWV Medical, Sydney, Australia). The body surface distance 
between  points  of  maximal  palpable  pulsation  at  carotid  and  femoral  arteries  was 
measured in millimetres.  A hand-held micromanometer-tipped probe was applied to the 
skin overlying the carotid and femoral arteries in turn, at the point of maximal palpable 
pulsation.  Arterial  waveforms  were  recorded  for  a  minimum  of  12  seconds  at  both 
carotid  and  femoral  sites.  The  pulse  wave  recorded  at  each  point  was  gated  to  a 
simultaneous electrocardiogram. The time delay between initial wave reflection at the 
proximal (carotid) artery and the distal (femoral) artery was measured with the “foot-to-
foot” method to give a value in milliseconds (figure 2.1). The time difference between   74 
successive  arterial  wave  reflections  and  the  body  surface  distance  between  the 
measurement  points  of  carotid  and  femoral  arteries  were  then  assimilated  by  the 
software program to calculate PWV in metres per second (m/s). The quality control 
parameters integral to the SphygmoCor™ software were used to determine the quality of 
arterial waveform and ECG recordings. The foot of the waveform and the R-wave of the 
ECG must be easily identified from at least three successive beats at each measurement 
point  to  calculate  PWV.  The  variation  in  heart  rate  between  carotid  and  femoral 
recordings must be less than 6%. PWV measurements must have a standard deviation of 
10%  or  less.  Three  PWV  measurements  meeting  these  quality  control  criteria  were 
recorded for each subject and averaged for analysis.  Pulse wave velocity data were 
transferred  to  a  personal  computer  and  collated  using  Microsoft  Excel  software  for 
Windows (Microsoft Corp., Seattle, Washington) before undergoing statistical analysis 
with  Prism  Graphpad  software  for  Windows  (Graphpad  Software  Inc.,  San  Diego, 
California, USA).   75 
Figure 2.1: 
Aortic  pulse  wave  velocity  (PWV)  calculation  using  the  “foot-to-foot”  method;  the  arterial  pressure 
waveform at the carotid and femoral arteries is gated to the R-wave of the electrocardiogram (ECG). 
PWV = L / ∆ T (L = Length between surface measurement sites in mm, ∆ T = transit time in m/s.) 
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2.2.3  Arterial diastolic waveform analysis 
Arterial pressure waveform analysis was performed and central and peripheral arterial 
compliance,  derived  from  a  modified  windkessel  model,  measured  using  the 
Hypertension  Diagnostic  incorporated  (HDI)  system  (HDI  pulse  wave  CR-2000; 
Hypertension  Diagnostics  Inc.,  Egan,  Minnesota,  USA).    As  mentioned  below,  this 
device was also used to measure heart rate and brachial blood pressure in all subjects.  
An acoustic transducer was applanated over the radial artery of the dominant arm. A 
wrist stabiliser was positioned on the wrist to gently immobilise the wrist and stabilise 
the  radial  artery  making  it  accessible  for  optimum  placement  of  the  arterial  pulse 
pressure sensor. The pressure sensor was positioned over the radial artery and held in 
place  using  a  holding  and  positioning  device  on  a  manually  adjustable  shaft.  Pulse 
pressure waveforms were recorded by placing the device over the point of maximal 
arterial pulsation. The applanating pressure was adjusted by rotating the knob on the top 
of the device until optimal waveforms were obtained.  A sphygmomanometer cuff was 
placed  around  the  upper  non-dominant  arm.    Heart  rate,  blood  pressure  and  arterial 
pressure waveforms were recorded for 30 seconds and analysed with integrated HDI 
software.  Three measurements were taken and averaged for off-line analysis. Using 
curve-fit analysis of the diastolic pulse waveform and a modified windkessel model of 
the circulation, the HDI software calculates derived measurements of large (central or 
‘capacitive’) artery compliance, small (peripheral or ‘oscillatory’) artery compliance and 
systemic vascular resistance, along with averaged heart rate and brachial blood pressure   77 
values.    Averaged  values  for  large  and  small  artery  compliance,  systemic  vascular 
resistance, heart rate and blood pressure data was transferred to a personal computer and 
collated  using  Microsoft  Excel  software  for  Windows  (Microsoft  Corp.,  Seattle, 
Washington) before undergoing statistical analysis with Prism Graphpad software for 
Windows (Graphpad Software Inc., San Diego, California, USA). 
 
2.2.4  Heart rate and brachial blood pressure measurement 
The  Hypertension  Diagnostic  Inc.  system  (HDI  pulse  wave  CR-2000;  Hypertension 
Diagnostics Inc., Egan, Minnesota, USA) was used to measure heart rate and blood 
pressure in all subjects.  As described above, heart rate was recorded for 30 seconds 
during  each  measurement  of  arterial  pressure  waveforms.    Also  during  this  time,  a 
brachial blood pressure reading was taken using a semi-automated sphygmomanometer.  
Heart rate and brachial blood pressure were recorded three times and averaged. 
 
2.2.5  Microvascular function 
Microvascular function was measured with Laser Doppler imaging and iontophoresis of 
endothelial-dependent and -independent vasodilators.[112, 146] 
Iontophoresis 
Two iontophoresis chambers were attached to the skin of the volar aspect of the right 
forearm  by  means  of  double-sided  adhesive  discs,  avoiding  hair,  broken  skin  and 
superficial veins.    78 
The  iontophoresis  chambers  (ION  6;  Moor  Instruments  Ltd.,  Axminster,  UK)  are 
constructed  from  Perspex  with  an  internal  platinum  wire  electrode.  Following 
application  to  the  skin,  the  chambers  were  connected  to  the  anode  and  cathode 
connections  of  the  iontophoresis  controller.  A  digital  multimeter  was  connected  in 
parallel to monitor voltage across the chambers (figure 2.2). As a constant current source 
was used, resistance values were calculated from the recorded voltages using Ohm’s 
law. 
Control of current delivery has been pre-programmed into the software for the Laser 
Doppler imager such that the current is switched on at the beginning of a scan and 
remains on until the start of the following scan. The current then either remains on for 
the  next  scan  or  is  switched  off  once  the  total  charge  has  been  delivered.  Current 
duration was determined by the time taken to complete each scan (50s) multiplied by the 
total number of scans. To limit the iontophoresis dose, low currents were used. The 
protocol involves incremental current delivery of four scans at 5 microamps, four at 10 
microamps, four at 15 microamps and two at 20 microamps, giving a total charge of 
8 mC. 
Drugs used:  2.5 ml of 1% acetylcholine chloride (Sigma Chemical Co., St. Louis, MO, 
U.S.A.) was introduced into the  anodal chamber; 2.5ml of 1% sodium nitroprusside 
(Sigma) was introduced into the cathodal chamber. The vehicle for both drugs was 0.5% 
sodium chloride solution.   79 
Fluid  was  prevented  from  escaping  by  placing  circular  32 mm  coverslips  over  the 
chambers. Thus both agents were delivered simultaneously during each period of current 
administration. 
 
Perfusion measurements 
Non-invasive  measurement  of  skin  perfusion  was  performed  with  a  Laser  Doppler 
Imager (Moor Instruments Ltd.) equipped with a red laser (wavelength 633 nm, power 
1 mW,  beam  diameter  1 mm).  The  laser  was  scanned  in  a  raster  fashion  over  both 
chambers  and  through  the  coverslips.  The  backscattered  light  was  collected  by 
photodetectors  and  converted  into  a  signal  proportional  to  perfusion  in  arbitrary 
perfusion (flux) units that are displayed as a colour-coded image on a monitor (figure 
2.2).  Perfusion  measurements  were  obtained  using  the  imager  manufacturer’s  image 
analysis software.  Analysis of perfusion measurements were performed off-line to yield 
the median flux value across approximately 700 measurement points. Twenty sequential 
scans  were  taken.  The  first  was  taken  as  a  control  prior  to  current  administration, 
followed by the protocol of fourteen scans described above, followed by five scans with 
no current administration. The biological zero was measured with a single scan taken 
during occlusion of arterial blood flow by inflation of a sphygmomanometer cuff to 
supra-systolic levels (200 mmHg).  During off-line analysis, the colour-coded images 
were used to trace the two-dimensional area of each chamber in turn to generate a region 
of interest (ROI) for each scan.  The integrated software then calculated median flux 
values from acetylcholine and sodium nitroprusside chambers for each scan.  These raw   80 
data were collated with Microsoft Excel software.  Professor William Ferrell, University 
of Glasgow, performed statistical analysis of the data using Microsoft Excel software, as 
discussed below. 
Using this method, I compared skin microvascular responses to endothelial-dependent 
(acetylcholine) and endothelial-independent (sodium nitroprusside) vasodilators.   81 
Figure 2.2: 
A) Schematic of experimental setup. Acetylcholine (ACh) was placed in the anodal chamber and sodium 
nitroprusside (SNP) in the cathodal chamber. A digital voltmeter (V) was connected between the two 
chambers. B) Backscattered light intensity provides the photo image and the Doppler-shifted component 
provides the flux image. Flux is colour-coded with lowest perfusion in dark blue and highest in dark red.  
Figure from Ramsey et al, 2002.[112] 
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2.2.6  Venous capacitance 
Forearm  venous  capacitance  was  measured  with  venous  occlusion  plethysmography 
using  mercury-in-silastic  strain  gauges  (D.E  Hokanson  inc.,  Bellevue,  USA)  placed 
around the non-dominant forearm approximately 10 cm from the olecranon process at 
the point of greatest circumference.  Just prior to measuring venous capacitance, the 
hand was excluded from the circulation with a wrist cuff inflated to 220 mmHg.  Venous 
capacitance was measured using the equilibration method – inflating the upper-arm cuff 
to 45 mmHg for 2 minutes and 30 seconds.  Rapid cuff inflators were used to inflate the 
cuffs.  Venous capacitance was recorded 3 times in each patient and averaged.  The 
voltage  readings  from  the  plethysmograph  were  transferred  through  a  MacLab/8E 
(ADInstruments,  Hastings,  United  Kingdom)  to  a  Macintosh  computer  (Apple 
Computers Inc., Cupertino, California, US) for analysis using Chart software (version 
3.2.8, ADInstruments) and then transferred to a personal computer for statistical analysis 
as detailed below.[147] 
 
2.2.7  Venous endothelial function 
Venous endothelial function was assessed using the modified Aellig dorsal hand vein 
technique.[134]  Figure 2.3 details a schematic representation of the experimental setup. 
A  suitable  dorsal  hand  vein  was  selected  and  cannulated  with  a  34-gauge  butterfly 
cannula.  Physiological (0.9% NaCl) saline was infused into the dorsal hand vein at a 
rate of 0.3 ml/minute for 30 minutes.   83 
After this period, the transducer was mounted over the selected vein via a tripod and 
venous  dilatation  in  response  to  congesting  pressure  of  45 mmHg,  applied  with  a 
brachial sphygmomanometer cuff, was measured.  This measurement was repeated three 
times and the average value used as the baseline range of venodilatation.  The saline 
infusion  rate  was  then  reduced  to  0.2  ml/minute.  A  second  line  was  added  to  the 
butterfly  cannula  and  a  concomitant  infusion  of  phenylephrine  was  commenced  to 
constrict the vein. The dosage of phenylephrine was increased as follows in a stepwise 
fashion between 1 and 2500 ng/minute.  Each dose was infused at 0.1 ml/minute for 6 
minutes  and  the  venous  response  measured  between  the  4
th  and  6
th  minute.  The 
phenylephrine  dose  that  produced  70%  venoconstriction  from  baseline  (ED70)  was 
determined  and  infused  for  the  remainder  of  the  study.  To  ensure  stable 
venoconstriction, the ED70 was infused for 12 minutes with venous responses being 
measured between 4 to 6 and 10 to 12 minutes.  When stable venoconstriction had been 
established, the saline infusion was reduced further to 1 ml/minute and a third line was 
added to the cannula.  
To assess endothelial-dependent venodilatation, a concomitant infusion of acetylcholine 
was commenced and increased sequentially at the following doses: 0.1, 1, 5, 10, 50 
nmol/minute up to a maximum dose of 100 nmol/minute. Each dose was infused at 0.1 
ml/minute for 6 minutes, with the venous response being measured between the 4
th and 
6
th minute.  Acetylcholine causes endothelial-dependant venodilatation at low doses and 
smooth muscle-dependent venoconstriction at higher doses. The dose of acetylcholine 
was increased until venodilatation had peaked and then diminished to 20% below the   84 
peak, at which point all infusions were discontinued and the butterfly cannula removed.  
The maximum venodilatation by acetylcholine was then calculated to give a measure of 
venous endothelial function.  The raw data were transferred to a personal computer and 
collated  using  Microsoft  Excel  software  for  Windows  (Microsoft  Corp.,  Seattle, 
Washington) before undergoing statistical analysis with Prism Graphpad software for 
Windows (Graphpad Software Inc., San Diego, California, USA). 
   85 
Figure 2.3: 
Schematic of experimental setup for the Aellig modified dorsal hand vein technique. A) Shows the mobile 
core over the collapsed vein. B) Shows the core position after vein dilatation in response to inflation of a 
sphygmomanometer cuff around the upper arm to a congesting pressure of 45 mmHg. Movement of the 
core within the linear variable differential transformer (LVDT) is converted into an output in volts that is 
graphed to give venous dilatation measurements. 
Adapted from Aellig WH, 1981.[134] 
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2.2.8  Blood tests 
All serum samples were taken from the antecubital fossa with the patient in the supine 
position for a minimum of 30 minutes prior to venesection. 
Serum  samples  for  urea  and  electrolytes  and  total  cholesterol  were  analysed  in  the 
Biochemistry Laboratory at the Gartnavel General Hospital Glasgow, using  standard 
methods. 
Blood samples for plasma NT-proBNP were taken directly to the research laboratory in 
the Western Infirmary and spun directly at 4˚C in a centrifuge for 15 minutes at 3,000 
rpm.  The supernatant was removed and put into separate freezer containers labelled 
with the patient subject number and stored in the freezer at -20˚C until the assays were 
analysed.   
The Roche Elecsys proBNP (Roche Diagnositics, East Sussex, England) immunoassay 
was  used  to  analyse  NT-BNP  (proBNP).  The  Elecsys  method  used  was  an 
electrochemiluminescent immunoassay on an Elecsys 2010 autoanalyser.  This has a 
within-assay and between-assay variability of 2.7 and 3.2% respectively.  The measuring 
range of the assay is 5–35,000 pg/ml.  The analytical sensitivity of the assay is 5 pg/ml. 
From work conducted on a healthy population, the following 95
th percentile figures were 
established as normal ranges dichotomised for age and sex (table 2.2).[148]  An elevated 
NT-proBNP was taken to be a value greater than the 95
th percentile for each age and sex 
category.   87 
The NT-proBNP immunoassays were completed by Dr Ian Morton who was blinded to 
clinical  details,  including  LV  systolic  function.    The  results  were  recorded  on  a 
Microsoft  Excel  spreadsheet  separate  from  any  other  clinical  details  or  patient 
identifiers. 
 
Table 2.2: 
 
95
th percentile according to age and sex of NT-proBNP for a healthy population.  
 
  NT-proBNP concentration pg/ml 
Age (years)  ≤ 64  65-69  70-74  ≥ 75 
Female  213.4  314.2  338.5  355.3 
Male  122.6  112.6  236  295.7 
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2.3  Power Calculation, Data Collection and Statistical Analysis 
 
2.3.1  Power calculation 
Dr Chris Weir from the Department of Statistics at the University of Glasgow provided 
statistical  advice  on  power  calculation  and  data  analysis.  I  performed  the  power 
calculation for this study using data from a prior validation study in our department 
using  the  SphygmoCor™  device  to  measure  PWV  (Dr  Arthur  Doyle  –  personal 
communication).  Ten subjects over 60 years of age with hypertension, normal renal 
function and no other manifest cardiovascular disease underwent carotid-femoral PWV 
assessment. Data from this study are appropriate for use in my power calculation as 
patients with hypertension are at risk of developing heart failure. The standard deviation 
of PWV in Dr Doyle’s sample was 0.45 m/s.  Therefore to detect a difference in PWV 
between  groups  of  at  least  0.66  m/s,  with  90%  power,  using  analysis  of  variance 
(ANOVA), eleven subjects per group were required. As multiple comparisons were to 
be  made,  Bonferroni  post-test  correction  was  to  be  employed  in  statistical  analysis. 
Significance level was set at 5% (between group differences were considered significant 
if p value <0.05). 
 
2.3.2  Data collection and statistical analysis 
Data  were  collated  with  Microsoft  Excel  Software  for  Windows  (Microsoft  Corp., 
Seattle, Washington). Statistical analysis and figure preparation was performed using   89 
Prism Graphpad software (Graphpad software Inc., San Diego, California, USA) apart 
from microvascular endothelial function data (Laser Doppler iontophoresis), which were 
analysed with Microsoft Excel.  Baseline characteristics of patients were summarised by 
mean  (standard  deviation)  for  continuous  variables  and  by  frequency  for  categorical 
variables.  Comparisons of continuous variables between groups were made using t-tests 
and ANOVA with Bonferroni correction for multiple comparisons. Data are presented as 
mean (standard deviation) in the text and as box (median and inter-quartile ranges) and 
whisker  (range)  plots  in  figures  apart  from  microvascular  and  venous  endothelial 
function data, which are presented as dose-response graphs.  
During analysis of Aellig dorsal hand vein data, it was apparent that there was marked 
variability  in  baseline  vein  diameter  between  subjects.    There  was  also  significant 
variability in responses to pre-constriction with phenylephrine and subsequent dilatation 
with  acetylcholine,  both  within  and  between  study  groups.    Although  stable 
venoconstriction  was  achieved  in  all  studies  included  in  analysis,  exact  ED70  (70% 
constriction  from  baseline)  was  not  achieved  in  all  studies.    Similarly,  there  was 
variability of venodilatation in response to acetylcholine within and between groups, 
with some subjects achieving peak venodilatation at low doses of acetylcholine, and 
some requiring much higher doses to achieve significant venodilatation.  As a result, 
there  was  substantial  variation  of  both  baseline  venoconstriction  values,  and  of 
acetylcholine concentrations used to achieve venodilatation. Consideration of the raw 
data  led  to  the  decision  to  use  percentage  change  venodilatation  from  baseline  in 
response to acetylcholine for analysis.  The data are presented for each study group as   90 
percentage  venous  dilatation  from  baseline  at  each  dose  of  acetylcholine,  and  were 
compared using analysis of variance with Bonferroni post-test correction for multiple 
comparisons. 
When considering the patient baseline characteristics, it is clear that there are differences 
in  potentially  confounding  variables  between  study  groups.  Specifically,  there  are 
differences in age and gender between groups, and the use of some medications such as 
nitrates, potassium channel activators and calcium antagonists varies between groups. 
Unfortunately the small sample size does not allow for multivariate analysis to correct 
for  these  variables.  It  must  be  acknowledged  that  less  stringent  inclusion/exclusion 
criteria would have resulted in recruitment of a larger sample size and the option to 
apply multivariate analysis if necessary. 
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Chapter 3 
 
 
 
Aortic Pulse Wave Velocity   92 
3.1  Introduction 
 
 
As discussed in chapter 1, the cause of heart failure in patients with HF-PSF is an area of 
controversy. The most commonly held view is that most have diastolic dysfunction, i.e. 
a disorder of LV relaxation and filling, as opposed to contraction and emptying.[40, 149]  
More  recently,  it  has  been  suggested  that  these  patients  have  abnormal  ventriculo-
vascular coupling, due to a combination of ventricular and vascular stiffening.[50, 53, 
54, 57, 59, 60, 150] 
An important determinant of LV afterload, and integral to ventriculo-vascular coupling, 
is large artery (aortic) stiffness.  As discussed in chapter 1, section 1.5.2, PWV has long 
been accepted as an excellent surrogate of aortic stiffness, and is generally considered to 
be the ‘gold standard’ method of assessing aortic stiffness non-invasively. 
Previous studies have compared vascular function between patients with HF-PSF and 
patients  with  systemic  hypertension  and/or  normal  subjects.    Co-morbidities  such  as 
diabetes mellitus and coronary heart disease were rarely matched between study groups 
during patient selection.  Vascular function has never been compared between HF-PSF 
and HF-RSF. 
In this chapter I present patient characteristics, blood pressure and heart rate data, and 
the results of PWV experiments. 
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3.2  Methods 
See chapter 2 for comprehensive documentation of methods employed in this study.  
 
3.2.1  Patient selection 
The aim of patient selection in this project was to allow comparison of vascular function 
between  both  common  types  of  HF-PSF  and  HF-RSF  and  an  appropriate  ‘real-life’ 
control group.  Therefore all subjects selected had coronary heart disease and patients 
with  co-morbidities  known  to  adversely  affect  vascular  function,  such  as  diabetes 
mellitus, uncontrolled hypertension and renal failure, were excluded. 
Three  groups  of  patients  (n=12  each)  were  selected,  matched  for  the  presence  of 
coronary  heart  disease:  1)  HF-PSF,  2)  HF-RSF  and  3)  controls  with  preserved  LV 
systolic function and no evidence of heart failure. 
 
3.2.2  Heart rate and blood pressure measurement 
The heart rate and one brachial blood pressure measurement was recorded over a 30 
second time period using the HDI device, as described in chapter 2.  This measurement 
was performed three times for each subject and averaged. 
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3.2.3  Aortic pulse wave velocity measurement 
Pulse  wave  velocity  was  measured  using  the  SphygmoCor
TM  applanation  tonometry 
system as described in chapter 2. 
Briefly, a sensor probe was used to measure the arterial waveform at carotid and femoral 
arteries.  The upstroke of the arterial waveform was gated to the R wave of the ECG 
using the ‘foot-to-foot’ method to calculate transit time of the arterial pulse wave along 
the  aorta,  ∆T.    This  value,  together  with  the  measured  surface  body  distance  in 
millimitres (mm) between both measurement points (carotid and femoral arteries), L, 
can be used to calculate PWV in m/s with the equation: PWV = L/∆T.   95 
3.3  Results 
 
3.3.1  Patient baseline characteristics 
 
Patient baseline characteristics and concomitant medications are shown in table 3.1. 
Table 3.1: 
 
Baseline characteristics of subjects, summarised by mean (standard deviation) for continuous variables 
and by frequency for categorical variables. Diuretic use classified by type: Thiazide (T) or Loop (L). Five 
patients in the control group were taking thiazide diuretics as anti-hypertensives. 
LVEF – left ventricular ejection fraction; NYHA – New York Heart Association; ACEI – angiotensin-converting 
enzyme inhibitor; ARB – angiotensin receptor blocker; HMG CoA – 3-hydroxy-3methylglutaryl coenzyme A 
 
GROUP 
 
Control 
n=12 
HF-PSF 
n=12 
HF-RSF 
n=12 
 
 
Age  
Boston Score 
Cholesterol 
NT-proBNP 
Systolic BP (mmHg) 
Diastolic BP (mmHg) 
Mean BP (mmHg) 
LVEF (%) 
 
Sex M/F 
 
History of 
hypertension 
 
NYHA Class (n) 
 
MEDICATION 
ACEI/ARB 
B-Blocker 
HMG CoA 
Diuretic 
(Thiazide/Loop) 
Aspirin/Antiplatelet 
Nitrate 
Ca Channel Blocker 
K Channel Activator 
 
Mean (SD) 
69.7 (8.3) 
N/A 
4.62 (1.18) 
186.9 (113.4) 
135.4 (14.1) 
70.1 (20.5) 
91.9 (26.5) 
63.2 (4.8) 
 
5/7 
 
 
10 
 
N/A 
 
n 
10 
9 
12 
5 (T) 
 
12 
1 
6 
6 
 
Mean (SD) 
77.3 (5.9) 
13.4 (2.1) 
4.56 (1.12) 
894.2 (446.9) 
146.2 (7.1) 
69.5 (7.3) 
95.0 (6.2) 
62.7 (8.1) 
 
4/8 
 
 
10 
 
II (11) III (1) 
 
n 
10 
9 
11 
12 (L) 
 
10 
2 
2 
1 
 
Mean (SD) 
73.9 (6.3) 
12.8 (1.7) 
4.7 (1.26) 
1416.1 (1033.7) 
134.0 (13.5) 
72.8 (10.6) 
93.2 (8.5) 
28.0 (9.4) 
 
8/4 
 
 
9 
 
II (10) III (2) 
 
n 
12 
10 
12 
12 (L) 
 
12 
4 
2 
2 
   96 
 
3.3.2  Blood pressure 
There  were  no  significant  differences  in  systolic,  diastolic  or  mean  blood  pressure 
between patient groups (figures 3.1, 3.2, and 3.3, respectively). 
Pulse pressure was significantly higher in the HF-PSF group compared with the HF-RSF 
group but not compared with controls (figure 3.4). 
 
Figure 3.1: 
Systolic blood pressure compared by patient group with analysis of variance (ANOVA). 
 
Control HF-PSF HF-RSF
110
120
130
140
150
160
p=ns* p=ns*
*ANOVA with Bonferroni correction
p=ns*
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Figure 3.2: 
Diastolic blood pressure compared by patient group with analysis of variance (ANOVA). 
 
Control HF-PSF HF-RSF
50
60
70
80
90
100 p=ns* p=ns*
*ANOVA with Bonferroni correction
p=ns*
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Figure 3.3: 
Mean blood pressure compared by patient group with analysis of variance (ANOVA). 
 
Control HF-PSF HF-RSF
75
80
85
90
95
100
105
110
115 p=ns* p=ns*
*ANOVA with Bonferroni correction
p=ns*
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Figure 3.4: 
Pulse pressure compared by patient group with analysis of variance (ANOVA). 
 
Control HF-PSF HF-RSF
0
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20
30
40
50
60
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90
p<0.05* p=ns*
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*ANOVA with Bonferroni correction
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3.3.3  Heart rate 
Subjects with HF-PSF had a significantly lower mean heart rate than both HF-RSF and 
control subjects: 51.6 (6.1); 60.3 (8.5) and 60 (8) beats per minute respectively, p<0.05, 
(figure 3.5). 
 
 
Figure 3.5: 
Heart rate compared by patient group with analysis of variance (ANOVA). 
 
Control HF-PSF HF-RSF
30
40
50
60
70
80 p<0.05* p<0.05*
p=ns*
*ANOVA with Bonferroni correction
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3.3.4  Aortic pulse wave velocity 
Pulse wave velocity was not recordable in one male patient from the HF-RSF group. 
Pulse wave velocity was significantly higher in HF-PSF subjects than in both HF-RSF 
and control groups: 10.7 (1.1); 8.9 (1.7) and 8.6 (2.1) m/s respectively, p<0.05 (figure 
3.6).  
 
Figure 3.6: 
Aortic pulse wave velocity (PWV) compared by patient group with analysis of variance (ANOVA). 
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3.4  Discussion 
 
The proportion of women was higher in the HF-PSF group than in both the HF-RSF and 
control groups.  Patients with HF-PSF were older than controls, but not patients with 
HF-RSF.  The  use  of  medications  known  to  modify  vascular  smooth  muscle  and 
endothelial  function,  particularly  angiotensin-converting-enzyme  inhibitors  (ACEI), 
angiotensin receptor blockers (ARB), 3-hydroxy-3-methylglutaryl coenzyme A (HMG 
Co-A) reductase inhibitors, aspirin and beta-blockers, was similar between groups.  The 
main difference in medications between groups was the higher use of diuretics in both 
heart failure groups, compared with controls.  All three groups had similar total serum 
cholesterol levels.  NT-proBNP was significantly elevated in both the HF-PSF and HF-
RSF groups compared with controls (p<0.05), in keeping with the clinical diagnosis of 
heart failure (table 3.1).  There was a trend to a higher mean plasma concentration of 
NT-proBNP in patients with HF-RSF than was observed in the HF-PSF group (1416.1 
[1033.7] pmol/l versus 894.2 [446.9] pmol/l, respectively).  However, this difference 
was not statistically significant (p=0.12, t-test) and was accounted for by one outlier in 
the HF-RSF group, who had a plasma NT-proBNP concentration of 4319 pmol/L.  New 
York Heart Association functional class and Boston score were similar in both heart 
failure groups. 
Heart failure with preserved LV systolic function was associated with elevation of PWV, 
which is related to the properties of the vessel wall by the Moens-Korteweg equation,   103 
and  has  long  been  accepted  as  a  surrogate  marker  of  arterial  stiffness  and  vascular 
remodelling.[65] Increased PWV in HF-PSF has not previously been reported.  More 
importantly, PWV was significantly elevated in my cohort of patients with HF-PSF, 
compared to controls and patients with HF-RSF, despite all three groups of patients 
being  matched  for  underlying  arterial  disease  (i.e.  having  coronary  heart  disease), 
implying that HF-PSF is indeed associated with greater arterial stiffness. 
Patients with HF-PSF had a significantly higher pulse pressure than patients with HF-
RSF, independent of mean arterial pressure.  Pulse pressure is closely related to PWV.  
As  discussed  in  section  1.5:  when  PWV  rises,  pulse  waves  are  reflected  from  the 
peripheral vasculature to the proximal aorta  earlier in the cardiac cycle, augmenting 
central arterial pressure during systole rather than diastole, resulting in elevated central 
pulse pressure.[70]  Pulse pressure is also influenced by height and age, with central 
pressure augmentation being more marked in shorter, older individuals.[151] This may 
be important in HF-PSF patients who are more likely to be older and female, as noted in 
epidemiological studies.[22, 23]  On review of the blood pressure data, patients with 
HF-PSF displayed a trend towards higher systolic blood pressure, accounting for the 
observed difference in pulse pressure. Another factor influencing pulse pressure, albeit 
to a lesser degree than PWV, is heart rate, with slower heart rates resulting in higher 
pulse pressures.[70]  My patients with HF-PSF had slower heart rates than the other two 
groups and this may have contributed to the elevated pulse pressure values observed in 
this particular cohort.     104 
The PWV and pulse pressure data presented above support my hypothesis that patients 
with HF-PSF have increased aortic stiffness. Increased aortic stiffening is likely to be 
implicated in the pathophysiology of HF-PSF by causing widening of the pulse pressure, 
reduced  coronary  perfusion,  increased  LV  wall  stress,  development  of  LVH  and 
increased  myocardial  oxygen  demand.    All  of  these  factors  may  result  in  impaired 
ventriculo-vascular coupling, elevation of LVEDP and the clinical syndrome of HF-PSF. 
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Analysis of Arterial Diastolic Pressure Waveforms 
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4.1  Introduction 
 
 
As I discussed in section 1.5.3, the arterial pressure waveform is a composite of incident 
and reflected waves.  Wave reflection occurs at points of impedance mismatch, such as 
vessel bifurcation and is also influenced by the diameter and contractile properties of the 
resistance arterial bed.  The point at which the reflected wave returns to the proximal 
aorta is dependent upon the speed with which the incident wave travels along the aorta, 
i.e.  PWV.    In  health  the  reflected  wave  arrives  in  the  proximal  aorta  in  diastole, 
augmenting  diastolic  pressure  and  facilitating  coronary  artery  flow.    However,  with 
progressive arterial stiffening PWV increases and the reflected wave arrives earlier in 
diastole and may arrive during systole.  The reflected wave superimposes on the incident 
systolic wave, augmenting systolic blood pressure.  This early return of the reflected 
wave during systole results in reduced diastolic blood pressure and widening of the pulse 
pressure.  As I mentioned in chapter 1, section 1.4.6, this phenomenon has profound 
detrimental effects on ventriculo-vascular coupling, which is likely to be implicated in 
the pathophysiology of HF-PSF. 
Using  a  modified  windkessel  model  of  the  circulation,  it  is  possible  to  analyse  the 
contour of the arterial pressure waveform during diastole.  With this method, one can 
determine the relative contributions of incident and reflected waveforms making up the 
contour of the composite arterial pressure waveform during diastole.  At the beginning 
of diastole, following aortic valve closure, the incident arterial pressure wave decays as 
pressure in the proximal aorta falls.  The elastic recoil of the aorta determines the speed   107 
of decay.  In healthy young individuals the aorta is rich in elastic fibres, buffering the 
incident wave and resulting in slow decay of the diastolic arterial pressure waveform.  
When the aorta loses elasticity, for example due to aging or systemic hypertension, its 
buffering effect is reduced.  As a result the incident wave rises sharply during systole 
and decays rapidly in diastole.  When described in the context of a windkessel model of 
the circulation, the elastic recoil of the large arteries during diastole is termed ‘capacitive 
compliance’. 
The second component of the arterial pressure waveform during diastole is the reflected 
pressure wave.  As mentioned above, the point at which the reflected wave arrives in the 
proximal aorta is dependent on the speed at which the incident wave is conducted along 
the  aorta,  the PWV,  and  the  contractile  properties  of  the  peripheral  vessels.    In  the 
windkessel model of the circulation, the contractile properties of the peripheral vessels 
are termed ‘oscillatory compliance’. 
In this chapter, I will detail the results of diastolic pressure waveform analysis in patients 
with HF-PSF, HF-RSF and controls. 
 
4.2  Methods 
 
Full details of the methods employed in this study are documented in chapter 2. 
Arterial  diastolic  pressure  waveform  analysis  was  performed  using  an  applanation 
tonometry  technique  and  a  specifically  designed  analysis  and  software  system  (HDI   108 
Pulse wave CR-2000; Hypertension Diagnostics Inc.), as described in more detail in 
chapter 2.  Arterial waveforms were recorded from the radial artery over a 30 second 
time  period.    This  protocol  was  performed  three  times  and  the  data  analysed 
automatically  by  the  integrated  software.  Using  curve-fit  analysis  of  the  diastolic 
pressure  waveform  and  a  modified  windkessel  model  of  the  circulation,  the  HDI 
software  calculates  derived  measurements  of  large  (central  or  ‘capacitive’)  artery 
compliance, small (peripheral or ‘oscillatory’) artery compliance and systemic vascular 
resistance. 
 
4.3  Results 
 
4.3.1  Patient baseline characteristics 
Patient  baseline  characteristics  along  with  heart  rate  and  blood  pressure  data  are 
presented in chapter 3. 
 
4.3.2  Arterial diastolic pressure waveform analysis 
Acceptable waveforms were not obtainable in one subject from the HF-RSF group. 
Derived values for large (central) arterial compliance (termed C1), small (peripheral) 
arterial  compliance  (termed  C2)  and  systemic  vascular  resistance  were  compared 
between  subject  groups.  No  significant  differences  were  detected  between  groups 
(figures 4.1, 4.2, 4.3. and table 4.1.).   109 
Figure 4.1: 
Large artery compliance compared by patient group with analysis of variance (ANOVA). 
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Figure 4.2: 
Small artery compliance compared by patient group with analysis of variance (ANOVA). 
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Figure 4.3: 
Systemic vascular resistance compared by patient group with analysis of variance (ANOVA). 
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Table 4.1: 
 
Large artery compliance (C1), small artery compliance (C2) and systemic vascular resistance 
compared by patient group with analysis of variance (ANOVA). 
 
 
PARAMETER  CONTROL 
n=12 
HF-PSF 
n=12 
HF-RSF 
n=11 
p-value 
 
 
Large Artery Compliance (C1)  
(ml/mmHg) 
Small Artery Compliance (C2)   
(ml/mmHg) 
Systemic Vascular Resistance 
 (dyne.s cm-5) 
 
Mean (SD) 
 
1.103 (0.42) 
 
0.029 (0.009) 
 
1705.8 (197.4) 
 
 
Mean (SD) 
 
1.004 (0.29) 
 
0.025 (0.009) 
 
1798.8 (336.3) 
 
 
Mean (SD) 
 
1.289 (0.55) 
 
0.033 (0.019) 
 
1822.1 (659.1) 
 
 
 
 
ns 
 
ns 
 
ns 
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4.4  Discussion 
 
Pulse wave analysis using the HDI device yielded values below the reported normal 
range for both large and small vessel compliance in all three patient groups, but no 
significant differences between groups.  I found this surprising in light of the PWV 
results  in  the  same  subject  groups,  demonstrating  that  HF-PSF  subjects  have 
significantly higher PWV, and therefore, arterial stiffness.   
The  discrepancy  between  HDI  and  PWV  results  is  likely  to  be  due  to  the  different 
applanation tonometry techniques.  The HDI technique has predominantly been used in 
previous  studies  to  identify  abnormalities  of  arterial  compliance  in  patients  at 
cardiovascular risk, e.g. diabetics,[94] or patients with established heart failure [152] 
compared with normal subjects.  It has also been employed effectively to demonstrate 
changes in arterial compliance in response to pharmacological therapies.[153, 154] 
The  fact  that  we  used  the  HDI  device  to  compare  patients  who  all  had  established 
atherosclerotic disease may have reduced the ability of the technique to differentiate 
between groups and resulted in no significant inter-group differences being detected.  
Another factor that may account for the discrepancy between PWV and HDI results is 
the data analysis method.  PWV is determined using a simple equation.  On the other 
hand, the HDI system uses curve-fit analysis of the diastolic pressure waveform and 
estimates other variables such as stroke volume and cardiac output from the systolic 
upstroke of the arterial pressure wave, heart rate, brachial blood pressure, age and body   114 
surface area.  As I discuss in chapter 3, there are differences in age and gender between 
groups.  These differences are likely to confound the data upon which the HDI software 
bases calculations of stroke volume and cardiac output, and subsequent calculations of 
arterial properties.  Finally, a more simple explanation is that there may not have been 
enough patients studied to detect a difference between groups using this technique. 
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Chapter 5 
 
 
 
 
Microvascular Endothelial and Smooth Muscle Function 
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5.1  Introduction 
 
 
The vascular endothelium is integral to maintaining normal vessel tone and function and, 
therefore, normal ventriculo-vascular interaction.[76]  As mentioned in section 1.5.6, 
arterial endothelial dysfunction has been well documented in HF-RSF [98-102] and is 
thought  to  be  secondary  to  neurohumoral  and  inflammatory  activation.[155-157]  
Whether HF-PSF is associated with endothelial dysfunction is, however, unknown.  In 
this chapter I detail the results of microvascular function compared between patients 
with HF-PSF, HF-RSF and controls. 
 
5.2  Methods 
 
Iontophoresis  combined  with  Laser  Doppler  imaging  was  performed  as  previously 
described in chapter 2. 
Acetylcholine  chloride  was  introduced  into  the  anodal  chamber  and  sodium 
nitroprusside  was  introduced  into  the  cathodal  chamber.    Current  applied  to  these 
chambers results in iontophoresis of both agents across the skin to exert their effects on 
the microvasculature.  During iontophoresis, a laser scanned both chambers to determine 
skin perfusion – a measure of vasodilatation. 
The  data  were  analysed  off-line  and  study  groups  were  compared  using  repeated 
measures 2-way ANOVA (Microsoft Excel software for Windows). 
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5.3  Results 
 
5.3.1  Patient characteristics 
Baseline  patient  characteristics  along  with  heart  rate  and  blood  pressure  data  are 
presented in chapter 3. 
 
5.3.2  Laser Doppler iontophoresis 
Vasodilatation  in  response  to  acetylcholine  was  similar  in  both  heart  failure  groups.  
Both heart failure groups displayed an impaired vasodilator response to acetylcholine 
compared  with  controls  (HF-RSF  versus  control  p=0.0003,  HF-PSF  versus  control 
p=0.00099, HF-PSF versus HF-RSF p=ns, ANOVA) as illustrated in figure 5.1. The 
heart  failure  groups  also  had  similar  peripheral  vasodilatation  responses  to  sodium 
nitroprusside.    These  endothelium-independent  responses  were  also  significantly 
reduced when compared with controls (HF-RSF versus control p=0.012, HF-PSF versus 
control  p=0.006,  HF-PSF  versus  HF-RSF  p=ns,  ANOVA),  as  demonstrated  in 
figure 5.2. 
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Figure 5.1: 
Peripheral microvascular responses to acetylcholine. Doppler measurement of vasodilatation is expressed 
as arbitrary perfusion units (PU). Cumulative charge in micro-Coulombs (mC) is the total charge delivered 
during iontophoresis. 
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Figure 5.2: 
Peripheral microvascular responses to sodium nitroprusside. Doppler measurement of vasodilatation is 
expressed  as  arbitrary  perfusion  units  (PU).  Cumulative  charge  in  micro-Coulombs  (mC)  is  the  total 
charge delivered during iontophoresis. 
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5.4  Discussion 
 
 
The data presented in this chapter are the first to demonstrate that HF-PSF subjects have 
impaired microvascular responses to both acetylcholine and sodium nitroprusside.  This 
suggests  that,  rather  than  being  solely  a  primary  disorder  of  endothelial  function, 
impaired control of vascular tone in HF-PSF also reflects significant vascular smooth 
muscle dysfunction.  It should be emphasised that all patients in this study had coronary 
artery  disease,  which  is  known  to  be  associated  with  impaired  peripheral  vascular 
responses  to  vasodilators.[158]  These  data  show  that  patients  with  HF-PSF  have 
impaired peripheral microvascular vasodilator function over and above what would be 
expected with atherosclerotic disease alone.  These results also show that the degree of 
microvascular dysfunction is similar in both HF-PSF and HF-RSF patients, implying 
that the vascular abnormalities seen in heart failure are not exclusively due to reduced 
LV systolic function.  Apart from the difference in LV systolic function, the heart failure 
groups were otherwise well matched.  They had similar clinical symptoms and signs, as 
evidenced  by  NYHA  class  and  Boston  scores  and  both  displayed  significant 
neurohumoral  activation,  with  equivalent  elevation  of  plasma  NT-pro-BNP 
concentration.  
Impaired responses to both endothelial-dependent and -independent vasodilators, have 
been previously demonstrated in some,[100, 113, 159-161] but not all [78, 101, 102] 
studies  in  patients  with  HF-RSF.  One  of  the  most  important  potential  mechanisms 
causing  endothelial  dysfunction  is  oxidative  stress,  leading  to  production  of  reactive   121 
oxygen species and inactivation of nitric oxide, a key factor in the control of vasomotor 
tone.[162]  There is a significant body of evidence suggesting that oxidative stress is an 
important  pathophysiological  process  in  the  development  of  arterial  endothelial 
dysfunction in HF-RSF.[18, 105]   Other factors, such as maladaptive overactivity of the 
RAAS [79] and circulating endothelin [103] have been implicated as potential causes of 
arterial endothelial dysfunction in HF-RSF.  The vascular endothelium is integral to 
maintaining  normal  vessel  tone  and  function  and,  therefore,  influences  arterial 
stiffness.[76]  Impaired arterial endothelial function is associated with reduced arterial 
compliance in older individuals,[106] which may be relevant in patients with HF-PSF 
who  tend  to  be  elderly.    It  is  not  yet  known  whether  or  not  any  of  these 
pathophysiological processes are responsible for vascular endothelial and smooth muscle 
dysfunction in patients with HF-PSF 
Notwithstanding  the  mechanisms  causing  it,  it  would  appear  that  the  ‘heart  failure 
syndrome’, regardless of aetiology, is associated with impaired peripheral microvascular 
vasodilator function.   
To date, peripheral vascular function in HF-PSF has not been extensively studied.  The 
results  in  this  chapter  show  that  patients  with  HF-PSF  have  profoundly  reduced 
peripheral microvascular responsiveness.  In other words, HF-PSF is associated with a 
markedly impaired capacity to regulate vascular tone and function.  If this phenomenon 
is present across multiple vascular beds it may be implicated in the pathophysiology of 
HF-PSF  by  potentially  reducing  coronary  artery  flow,  increasing  peripheral 
vasoconstriction and impairing ventriculo-vascular coupling.   122 
This  raises  the  possibility  that  modification  of  vascular  endothelial  and/or  smooth 
muscle function will prove to be a useful therapeutic strategy in the future management 
of patients with HF-PSF. 
Although it is possible that the mechanisms causing impaired vascular reactivity are 
similar in both types of heart failure, evidence is currently lacking.  Further studies of 
the mechanisms causing vascular endothelial and smooth muscle dysfunction in HF-PSF 
are required to clarify this issue. 
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Venous Function 
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6.1  Introduction 
 
In this chapter I present the results of venous function studies.  Results of both venous 
capacitance and venous endothelial function experiments are detailed and discussed. 
As  I  discussed  in  section  1.5.9,  venous  capacitance  and  control  of  venous  tone  are 
important  determinants  of  LV  pre-loading  conditions  that,  if  abnormal,  could 
theoretically contribute to increased LVEDP and the clinical syndrome of heart failure. 
Venous capacitance has been studied in the context of HF-RSF, where reduced venous 
capacitance  is  associated  with  reduced  exercise  capacity  in  that  patient  group.[125] 
Reduced venous capacitance has also been demonstrated to correlate with more severe 
symptoms of heart failure and elevated pulmonary artery pressure in patients with HF-
RSF.[126]  There is no information regarding venous capacitance in patients with HF-
PSF.  Patients with HF-PSF are more sensitive to the effects of vasodilators and diuretics 
on LV filling pressure, suggesting that venous capacitance is reduced.[131, 132]  There 
have, until now, been no studies of venous capacitance in patients with HF-PSF.   
As  mentioned  above,  reduced  venous  capacitance  may  be  an  important 
pathophysiological factor in the development of HF-PSF as there is evidence to suggest 
that venous capacitance influences LVEDP and  symptoms in patients with HF-RSF.   
The venous endothelium is integral to control of venous tone and, therefore, venous 
capacitance.  The most widely accepted method of assessing venous endothelial function 
is the modified Aellig dorsal hand vein technique.  In chapter 1, I provide an overview   125 
of the development of the dorsal hand vein technique and a summary of the data from 
previous studies of venous endothelial function.  Most of these studies were performed 
in healthy individuals, however there are some data indicating that patients with HF-RSF 
have impaired venous endothelial function.  Venous endothelial function has never been 
assessed in patients with HF-PSF. 
In the following text I will detail the methodology and results of venous capacitance and 
venous endothelial function measurement in subjects with HF-PSF, subjects with HF-
RSF and appropriate controls. 
 
6.2  Methods 
 
Full  details  of  the  methodology  used  to  measure  venous  capacitance  and  venous 
endothelial function are described in chapter 2.  Briefly, forearm venous capacitance was 
measured  with  venous  occlusion  plethysmography  using  mercury-in-silastic  strain 
gauges.  Just prior to measuring venous capacitance, the hand was excluded from the 
circulation with a wrist cuff inflated to 220 mmHg.  Venous capacitance was measured 
using the equilibration method – inflating the upper-arm cuff to 45 mmHg for 2 minutes 
and  30  seconds.    Venous  capacitance  was  recorded  three  times  in  each  patient  and 
averaged.[147] 
Venous endothelial function was measured using the modified Aellig dorsal hand vein 
technique.[134]  A suitable dorsal hand vein was cannulated.  Baseline venous dilatation   126 
in response to an upper arm sphygmomanometer cuff at 45 mmHg was measured.  The 
vein was pre-constricted with phenylephrine, infused in incremental doses until 70% 
venoconstriction  from  baseline  was  achieved  (ED70).    While  maintaining  the 
phenylephrine  infusion  to  achieve  steady-state  ED70,  a  concomitant  infusion  of 
acetylcholine  was  commenced  and  incremented  to  stimulate  endothelial-dependent 
venodilatation.  As acetylcholine causes smooth muscle-dependent venoconstriction at 
high  doses  I  pre-determined  that  each  study  would  be  discontinued  when  maximal 
venodilatation  had  peaked  and  then  fallen  by  20%  of  the  maximum  vein  diameter 
achieved. 
 
6.3  Results 
 
6.3.1  Patient baseline characteristics 
Patient  baseline  characteristics  along  with  heart  rate  and  blood  pressure  data  are 
presented in chapter 3. 
 
6.3.2  Venous capacitance 
Venous capacitance was higher in HF-RSF subjects compared to HF-PSF subjects: 1.75 
(0.41), 1.34 (0.34) ml/100 ml forearm volume respectively, p<0.05, ANOVA (figure 
6.1). 
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Figure 6.1: 
Venous capacitance (VC) compared by patient group with analysis of variance (ANOVA). 
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6.3.3  Venous endothelial function 
It was not technically possible to conduct a dorsal hand vein study on two patients from 
the HF-PSF group, and on 1 patient from each of the HF-RSF and control groups. There 
was  marked  variability  in  baseline  vein  diameter  between  subjects.  There  was  also 
significant  variability  in  responses  to  pre-constriction  with  phenylephrine  and 
subsequent  dilatation  with  acetylcholine,  both  within  and  between  study  groups.  
Although stable venoconstriction was achieved in all studies included in analysis, exact 
ED70 (70% constriction from baseline) was not achieved in all studies.  Similarly, there 
was  variability  of  venodilatation  in  response  to  acetylcholine  within  and  between 
groups, with some subjects achieving peak venodilatation at low doses of acetylcholine, 
and some requiring much higher doses to achieve significant venodilatation.  As a result, 
there  was  substantial  variation  of  both  baseline  venoconstriction  values,  and  of 
acetylcholine concentrations used to achieve venodilatation. Consideration of the raw 
data  led  to  the  decision  to  use  percentage  change  venodilatation  from  baseline  in 
response to acetylcholine for analysis.  The data are presented for each study group as 
percentage  venous  dilatation  from  baseline  at  each  dose  of  acetylcholine,  and  were 
compared using analysis of variance with Bonferroni post-test correction for multiple 
comparisons. The number of subjects receiving each dose of acetylcholine is shown in 
table 6.1. 
Venodilatation in response to acetylcholine appeared to be similarly poor in both heart 
failure groups compared with controls, although there were no statistically significant 
differences  in  responses  between  groups  (figure  6.2).    Both  heart  failure  groups   129 
displayed a trend towards more pronounced venoconstriction at high dose acetylcholine 
compared with controls. 
 
Figure 6.2: 
Venous dilatation with acetylcholine (ACh) following pre-constriction with phenylephrine compared by 
patient group. Responses are presented as percentage change from baseline with each dose of ACh. 
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Table 6.1: 
Number of patients per study group at each acetylcholine (ACh) dose. 
 
ACh dose (nmol/min)  0.1  1  5  10  50  100 
Number per study group 
          HF-PSF 
          HF-RSF 
          Control 
 
10 
11 
11 
 
10 
11 
11 
 
9 
11 
11 
 
9 
11 
9 
 
7 
9 
6 
 
4 
4 
3 
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6.4  Discussion 
 
Venous capacitance appeared to be lower in the controls than in patients with HF-RSF.  
Perhaps the more interesting finding was that the patients with HF-PSF had a similar 
venous capacitance to the controls and lower venous capacitance than patients with HF-
RSF.  As I mentioned in the introduction to this chapter, patients with HF-PSF are more 
sensitive to the effects of vasodilators and diuretics on LV filling pressures, suggesting 
an abnormality of venous capacitance.[131, 132]  Higher venous capacitance will result 
in a greater capacity of the circulation to accommodate a higher circulating volume 
without resulting in elevation of the LVEDP.[120]  It has been shown that patients with 
HF-RSF display a preserved venodilator response to atrial natriuretic peptide [128] and 
an  appropriate  venous  capacitance  rise  in  response  to  nitric  oxide  [98]  despite 
impairment of arterial endothelial function.  Patients with HF-PSF may have a reduced 
venous  response  to  endogenous  nitric  oxide  leading  to  a  failure  to  increase  venous 
capacitance - which could then be considered to be a dysfunctional response.  Another 
possibility is that this cohort of patients with HF-PSF had higher resting venous pressure 
than patients with HF-RSF.  This would result in measurements starting at a steeper 
point on the venous compliance curve, and less change in venous volume in response to 
congesting pressure.   
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The data from the Aellig experiments suggest that patients with HF-PSF and HF-RSF 
may have impaired venous endothelial function compared to control subjects.  However, 
these  apparently  different  responses  to  acetylcholine  did  not  reach  statistical 
significance. 
Both heart failure groups displayed a trend towards more pronounced venoconstriction 
at high dose acetylcholine compared with controls.  Despite the graph appearance, it 
must  be  borne  in  mind  that  not  all  patients  in  each  group  received  high  dose 
acetylcholine,  due  to  the  pre-determined  end-point  of  a  20%  fall  from  peak 
venodilatation being reached at lower doses of acetylcholine for most patients.  The 
point where the difference between heart failure groups and the control group is most 
apparent is during infusion of 100 nmol/minute acetylcholine.  The number of patients 
who received this dose in each group was 6 HF-PSF patients, 4 HF-RSF patients and 3 
control patients (table 6.1). 
The fact that it was not technically possible to perform a dorsal hand vein study in all 
patients,  coupled  with  the  variability  of  responses  to  both  constricting  and  dilating 
agents, makes it difficult to draw firm conclusions from these results. 
The findings of these studies of venous function raise the possibility that patients with 
HF-PSF  have  abnormal  venous  capacitance  and/or  impaired  venous  endothelial 
function.  However, I do not claim to have defined the exact role of the venous bed in 
the pathophysiology of HF-PSF.  Although it remains possible that patients with HF-
PSF have impaired venous function, the venous capacitance results presented above are 
not conclusive and the Aellig experiments do not have enough statistical power to prove   132 
or  disprove  the  hypothesis  that  HF-PSF  is  associated  with  venous  endothelial 
dysfunction.  Further, larger studies are required to investigate venous function in HF-
PSF.   133 
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Heart failure has been recognised as an important public health burden for decades.  
Multiple epidemiology studies have indicated that a significant proportion of patients 
with heart failure have preserved LV systolic function.[22, 23]  Recently published data 
indicate that HF-PSF has increased in prevalence in the last 15 years,[26] and carries a 
similar prognosis to HF-RSF.[28]  Prior to these epidemiology studies, it was widely 
accepted  that,  in  the  absence  of  significant  valvular  heart  disease,  heart  failure  was 
caused by reduced LV systolic function.  The pathophysiology of HF-RSF has been 
extensively  studied  and  the  basic  principles  are  easy  to  understand,  reinforcing  the 
widespread assumption that HF-RSF is the predominant form of heart failure. 
The realisation that approximately half of all patients with heart failure have preserved 
LV systolic function has caused controversy.  The pathophysiology of HF-PSF is not 
easily explained and has been studied far less than HF-RSF.  Acceptance within the 
medical  community  of  HF-PSF  as  a  condition  in  its  own  right  has  been  slow, 
confounding the relative lack of research in the field.  In fact, increased awareness of the 
condition among doctors has probably contributed to the apparent increase in prevalence 
of HF-PSF over the last 15 years. 
Initial  investigation  into  the  pathophysiology  of  HF-PSF,  most  notably  by  Zile  and 
colleagues, demonstrated that subjects with HF-PSF have marked abnormalities of LV 
diastolic function, i.e. LV relaxation and filling.[31]  On the basis of this important 
finding, heart failure without significant impairment of LV systolic function was termed   135 
‘diastolic heart failure’, a definition which was widely adopted.  Despite the compelling 
evidence presented by Zile’s group, some questions remained regarding whether or not 
LV diastolic dysfunction is the only pathophysiological process causing HF-PSF. 
For example, diastolic dysfunction of the left ventricle is also very common in HF-
RSF,[43] suggesting that the volume overload associated with the heart failure syndrome 
may impair LV diastolic function, rather than LV diastolic dysfunction causing heart 
failure per se.  Supporting this view is the finding from several studies that non-invasive 
and invasive measures of LV diastolic function and pressure are load-dependent.[54, 
163]  This characteristic renders measures of diastolic function less reproducible, and 
there is poor correlation between LV diastolic dysfunction and the presence of heart 
failure in population-based echocardiography studies.[42] 
Another  issue  is  that  population-based  studies  have  revealed  the  paradox  that  LV 
diastolic dysfunction is as common in males as it is in females, whereas HF-PSF is more 
common in women.[43] 
Although LV diastolic dysfunction is likely to play an important role in the development 
of HF-PSF, it is unlikely to be the only pathophysiological factor. 
An  alternative  explanation  is  that  patients  with  HF-PSF  have  impaired  ventriculo-
vascular interaction, i.e. stiffening of both the left ventricle and the vasculature, leading 
to elevation of LVEDP and the heart failure syndrome.  Results of some studies would 
appear to support this hypothesis as combined ventricular and arterial stiffening has been 
demonstrated  in  patients  with  hypertension  and  elderly  females  who,  according  to 
epidemiology data, are more likely to develop HF-PSF.[53] Kawaguchi et al conducted   136 
one of the few studies investigating this concept in patients with HF-PSF.[54]  They 
demonstrated combined ventriculo-arterial stiffening in HF-PSF when compared with 
both hypertensive and normal individuals.  Although not conclusive, this growing body 
of evidence indicates that HF-PSF is unlikely to be purely a disorder of LV diastolic 
dysfunction, and may be due to a combination of ventricular and vascular abnormalities, 
as has been proposed by both Burkhoff and Kass.[59, 60]  
Increased arterial stiffness may result in abnormal ventriculo-arterial coupling, increased 
LV  wall  stress,  reduced  coronary  flow  and  aggravate  or  even  cause  the  clinical 
syndrome  of  heart  failure.  If  this  concept  is  expanded,  one  must  consider  that 
abnormalities of many facets of the vascular tree could potentially contribute to the 
development of heart failure. 
The vascular endothelium is integral to maintaining normal vessel tone and function and, 
therefore, normal ventriculo-vascular interaction.[76]  Vascular endothelial dysfunction 
has been well documented in HF-RSF.[98-102]  Whether HF-PSF is associated with 
endothelial dysfunction is, however, unknown.   
Additionally, reduced compliance of veins, leading to reduced venous capacitance, may 
also play an important role in the pathophysiology of HF-PSF.  Venous capacitance has 
been shown to be a determinant of LV pre-load conditions [121] and patients with HF-
PSF are particularly sensitive to the effects of vasodilators and diuretics on LV filling 
pressure,  suggesting  that  venous  capacitance  is  reduced.[131,  132]    If  venous 
capacitance can influence LV pre-load conditions then it follows that control of venous 
tone, via endothelial and smooth muscle activity, could also exert an effect on LV pre-  137 
load  and  potential  to  develop  heart  failure.  There  have  been  no  previous  studies  of 
venous function in patients with HF-PSF.   
The studies presented in this thesis were designed to further define the extent of vascular 
dysfunction  in  HF-PSF  and  to  test  the  hypothesis  that  vascular  dysfunction  is  more 
severe in HF-PSF than in HF-RSF and appropriate controls.  I aimed to investigate not 
only  arterial  stiffness  and  endothelial  function,  but  also  parameters  of  venous 
capacitance and endothelial function.  The studies were designed specifically to compare 
vascular function between patients with HF-PSF and HF-RSF.  I chose this method to 
determine whether or not vascular dysfunction is similar in both heart failure groups, 
suggesting that it is secondary to the heart failure syndrome regardless of aetiology, or 
more severe in HF-PSF, indicating that vascular dysfunction is potentially implicated in 
the aetiology of HF-PSF. 
As a control group, I recruited patients with coronary heart disease and preserved LV 
systolic function, rather than normal subjects.  It is extremely common for investigators 
to compare vascular function between patients with established cardiovascular disease, 
such  as  heart  failure,  and  normal  subjects.    This  method  is  well  recognised,  but 
undoubtedly  over-emphasises  abnormalities  of  vascular  function  in  the  group  under 
study.  I felt that for the purposes of this study it would be more appropriate to use a 
control group of patients at risk of developing heart failure, i.e. patients with coronary 
heart  disease,  who  might  also  be  expected  to  have  endothelial  dysfunction  and/or 
abnormal arterial compliance.  This method of patient selection provides a comparison 
of vascular function between patients who are representative of contemporary clinical   138 
practice,  and  will  help  to  determine  if  HF-PSF  is  truly  associated  with  vascular 
dysfunction, over and above what would be expected from coronary heart disease alone. 
The  vascular  experiments  were  chosen  to  provide  a  comprehensive,  non-invasive 
assessment of both arterial and venous function. 
Previous studies have suggested that arterial stiffness is increased in HF-PSF, but arterial 
stiffness has never been compared between HF-PSF and HF-RSF, as investigated in this 
study.  I also aimed to investigate aspects of vascular function that have never been 
assessed  in  HF-PSF,  such  as  arterial  endothelial  function,  venous  capacitance  and 
venous endothelial function. 
The  results  proved  interesting.  Arterial  stiffness,  measured  by  aortic  PWV,  was 
significantly elevated in HF-PSF compared to both HF-RSF and control groups, despite 
all three groups of patients being matched for underlying arterial disease (i.e. having 
coronary heart disease), implying that HF-PSF is indeed associated with greater arterial 
stiffness. These data were consistent with the observation that patients with HF-PSF had 
a significantly higher pulse pressure than patients with HF-RSF, independent of mean 
arterial pressure.  In contrast, the results of arterial diastolic waveform analysis were not 
especially illuminating, with no significant differences in derived parameters of arterial 
compliance being detected between the three study groups.  This was  surprising, as 
abnormal arterial compliance might be expected to be reflected in both increased PWV 
and abnormal arterial waveforms.  However, as I discuss in chapter 4, the complexity of 
the  diastolic  waveform  analysis  equation  to  derive  measures  of  arterial  compliance, 
coupled with the fact that all three groups had established arterial disease (coronary heart   139 
disease), is likely to have reduced the ability of the technique to differentiate between 
groups in this study.  It may also be possible that a larger sample size was required to 
demonstrate true differences between groups. 
The  Laser  Doppler  iontophoresis  experiments  revealed  that  HF-PSF  subjects  have 
impaired microvascular responses to both acetylcholine and sodium nitroprusside.  This 
suggests  that,  rather  than  being  solely  a  primary  disorder  of  endothelial  function, 
impaired control of vascular tone in HF-PSF reflects significant vascular smooth muscle 
dysfunction.    Although  a  novel  finding,  subjects  in  the  HF-RSF  group  displayed  a 
similar  pattern  of  microvascular  dysfunction.    Therefore  it  is  not  certain  if  arterial 
smooth  muscle  and/or  endothelial  dysfunction  is  secondary  to  the  inflammatory  and 
neurohumoral  activation  associated  with  the  heart  failure  syndrome,  as  has  been 
suggested in studies of HF-RSF, [155-157] or a primary pathophysiological factor in the 
development of either form of heart failure.  It is possible that endothelial and arterial 
smooth  muscle  dysfunction  is  both  cause  (in  HF-PSF)  and  effect  (in  HF-RSF)  – 
reflecting different pathophysiologies in the two conditions 
Venous capacitance appeared to be lower in the controls than in patients with HF-RSF.  
An interesting finding was that patients with HF-PSF had a similar venous capacitance 
to the controls and lower venous capacitance than patients with HF-RSF.  As I outline in 
chapter 6, the low venous capacitance in patients with HF-PSF may be representative of 
failure  to  increase  venous  capacitance  -  which  could  then  be  considered  to  be  a 
dysfunctional response.  Another possibility is that my cohort of patients with HF-PSF 
had  higher  resting  venous  pressures  than  patients  with  HF-RSF,  resulting  in   140 
measurements  starting  at  a  steeper  point  on  the  venous  compliance  curve,  and  less 
change in venous volume in response to congesting pressure. 
The  Aellig  dorsal  hand  vein  experiments  provided  some  interesting  information  on 
endothelial control of venous tone.  Both heart failure groups appeared to have impaired 
venodilatation in response to acetylcholine compared with controls, however this trend 
did not reach statistical significance.  Unfortunately it was not technically possible to 
complete an Aellig study in the whole cohort of patients, resulting in relatively small 
numbers used for data analysis.  This makes it difficult to draw any firm conclusions 
about  venous  endothelial  function  in  HF-PSF  on  the  basis  of  the  data  presented  in 
chapter 6. 
In  conclusion,  the  studies  presented  in  this  thesis  have  added  to  current  knowledge 
regarding  the  pathophysiology  of  HF-PSF.    After  initially  recognising  HF-PSF  as  a 
separate form of heart failure and appreciating the epidemiology, we have begun to 
understand the complex pathophysiology of HF-PSF.  Previous studies have shown that 
there is strong association between HF-PSF and LV diastolic dysfunction. 
This study has reinforced the theory that HF-PSF is associated with increased arterial 
stiffness, which in combination with increased LV stiffness is likely to result in impaired 
ventriculo-vascular  coupling.    This  process  is  likely  to  be  an  important 
pathophysiological factor in the development of HF-PSF.  A novel finding presented in 
this thesis is that endothelial and smooth muscle control of arterial tone, measured with 
Laser Doppler iontophoresis, was impaired in both HF-PSF and HF-RSF.  This may 
indicate a similar primary pathophysiological process, or indeed a similar response to inflammatory  and  neurohumoral  activation  in  heart  failure.  The  studies  of  venous 
capacitance and endothelial function I have presented suggest that venous function may 
be abnormal in HF-PSF.  The venous function data are not conclusive but may provide 
stimulus for further research in this rarely investigated field. 
Further studies are required, not only to investigate the pathophysiology of HF-PSF, but 
also to seek effective therapies for this extremely common form of heart failure. 
Examination of arterial stiffness, endothelial function and venous function during 
different cardiovascular loading conditions could provide interesting information on the 
generation of symptoms in HF-PSF. This could be achieved by conducting vascular 
function studies during exercise or acute decompensated fluid overload. As regards 
treatment of HF-PSF, there is a paucity of data. The CHARM-Preserved trial showed 
that treatment with the angiotensin receptor antagonist Candesartan resulted in mild 
clinical benefit in HF-PSF.[164] Treatment of HF-PSF with angiotensin receptor 
antagonists is the subject of other large, randomised, controlled trials such as I-
PRESERVE (comparing Irbesartan with placebo) and full results are awaited.[165] 
Novel therapies for HF-PSF are also being developed. For example, compounds which 
break glycation cross-links can attenuate the development of both left ventricular 
hypertrophy and arterial stiffness, an attractive combination when one considers 
potential pathophysiological factors in the development of HF-PSF. These compounds, 
such as Alagebrium [166] and ALT-711 [167], have been investigated in small studies 
but are not yet ready for use in larger clinical trials. It is my hope that the studies 
presented in this thesis will stimulate future studies into this important area of heart 
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